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Bone regeneration consists of a series of complex biological events, that in vivo, requires the highly 
coordinated presentation of biochemical cues to regulate these stages of healing. Taking inspiration 
from the natural healing process, a wide variety of growth factors are currently being released from 
tissue engineered scaffolds to aid in healing non-union fractures and bone defects. Currently, 
several scaffolding design techniques exist for releasing multiple growth factors with unique 
release profiles, which include polymer encapsulation, layer-by-layer fabrication, and core-shell 
construction, as well as growth factor delivery through other biological agents, such as plasmids 
and platelet-rich plasma. Several studies have suggested that the efficacy of multiple growth factor 
presentation may be influenced by several factors, including the sequence of presentation, and the 
dosage at various stages. Accordingly, building evidence suggests that in vivo growth factor 
presentation consists of highly coordinated temporal appearance, intricate crosstalk, and multi-
pathway signaling. Therefore, determining effective growth factor release schedules for 
incorporation in bone scaffolding requires an assay platform that, in some ways, begins to account 
for these complexities. For the purposes of our studies, we have developed a three-dimensional 
assay system, capable of supporting multiple cell types, that providing control over growth factor 
delivery presentation schedules. 
v 
To begin to understand the effects of multiple growth factor presentation on the stages of bone 
repair, we have used this assay system to assess cellular responses to a variety of growth factor 
delivery schedules with variations in sequence, length of delivery, and overlap in delivery. By 
varying these parameters, we have identified a schedule of PDGF and BMP-2 presentation capable 
of promoting angiogenic tubule formation in co-cultures of hMSCs and HUVECs. Based on this 
information, we have engineered a biomaterial-based system to controllably release this sequential 
schedule of PDGF and BMP-2 autonomously. This preprogrammed controlled release system was 
then incorporated with a three-dimensional, porous calcium phosphate scaffold, and resulting 
material properties and cellular responses were characterized. The following experiments and 
results aim to take inspiration from the in vivo bone healing milieu, and to use specific cellular 
responses to guide the fabrication of a truly biomimetic scaffolding system. 
vi 
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1.0 INTRODUCTION 
Bone tissue, like liver tissue, is one of the few tissues in the human body capable of some capacity 
of self-renewal, or regeneration [2-4]. As humans develop and grow, bone tissue is constantly 
undergoing phases of resorption (via osteoclasts) and reformation (via osteoblasts) [5]. These 
remodeling mechanisms are particularly useful when injury occurs to the skeletal system; in mild 
cases of injury, fractures may naturally remodel and therefore, require little medical intervention 
to heal [1]. However, when high impact, severe injuries cause complex fractures, successful 
healing may require titanium screws and plates, or in some cases, the addition of grafting material 
in the fracture space [6, 7]. 
While these practices are the gold-standard method of treatment [8, 9], there are still several 
issues that may arise during the course of treatment, such as misalignment of the bone or failure 
of the fracture to heal (non-union) [10]. In addition to these complications, the secondary surgeries 
and increased morbidities associated with autologous grafts have motivated efforts in the field of 
tissue engineering to create synthetic materials to encourage bone healing and overcome the 
hurdles of non-unions [11, 12]. A traditional tissue engineering approach is considered to consist 
of a mixture of cells, bioactive factors, and scaffolding [13, 14]. To effectively utilize these 
guidelines to create a successful biomaterial for fracture healing, it is advantageous to have an 
understanding of the cellular and physiological processes that constitute fracture healing. 
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Additionally, we may gain insight from current clinical methods of stimulating bone healing and 
their physiological relevance. 
1.1 CLINICAL DESCRIPTION OF FRACTURES 
In the US, 15.3 million fractures occur annually [2]; Fractures may occur as a result of stress, high 
impact, or other trauma and their likelihood of occurring may be increased by physiological 
conditions, such as osteoporosis [3]. Severity of fractures range from simple stable fractures, which 
may not even require casting or stabilization and take several weeks to heal, to complex, 
comminuted fractures, which may require multiple surgeries and external or internal fixation. The 
likelihood for successful healing also depends on several physiological factors; for example, the 
bone regeneration process has been shown to be hampered in individuals with compromised 
immunological systems due to diabetes, tobacco use, and aging [4]. 
1.1.1 Timeline of Normal Healing Events 
In successful fracture healing, a stage-wise series of events orchestrate new bone formation. 
Following injury, a hematoma forms at the site of fracture, which will be swollen and undergo 
inflammation for approximately one week [15, 16]. For fracture sites that can be reduced so that 
they are separated by less than 200μm, the fracture may be sufficiently stabilized to prevent 
micromotion, allowing the fracture to heal via primary healing [7, 17], that is, without the 
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formation of a fracture callus. For fracture with larger gaps that are subject to micromotion, healing 
occurs via secondary healing [7], a multi-stage process illustrated in Figure 1. Following 
inflammation in secondary healing, a soft callus, comprised of spongy, cartilaginous granulation 
tissue forms in the fracture space over the next 4-8 weeks [15]. During this phase, angiogenic 
infiltration of the soft callus occurs, bringing circulating cells into the fracture space [16, 18]. 
Subsequently, a hard callus, or the formation and mineralization of new bone will begin to bridge 
the gap, and typically fill the fracture space within 8-12 weeks after injury [18]. Finally, bone 
remodeling will occur, a stage that may last several years and involves the replacement of woven 
bone with more highly organized lamellar bone through the activity of osteoblasts (bone forming 
cells) and osteoclasts (bone resorbing cells)[15].   
Figure 1. Timeline of fracture healing events during secondary healing. Adapted from Einhorn et. 
al., 2015 [19]. 
Depending on fracture type, location and severity, methods of treatment may involve 
casting, surgery, and the placement of stainless steel or titanium hardware to mechanically stabilize 
bone fragments as they heal [20, 21]. However, several problems may arise during fracture healing, 
such as infection, malunion (a fracture that heals out of alignment) and nonunion (fractures that do 
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not heal within a normal timeframe) [22-24]. These cases often necessitate additional measures 
(beyond casting and the use of plates and screws) to facilitate healing [6].   
1.2 CLINICAL NEED FOR ASSISTED BONE HEALING 
Of the 15.3 million fractures occurring in the US, 5-10% result in non-unions, clinically meaning 
that are no observable signs of healing over time and that biological progress has ceased without 
fracture union occurring [7, 8]. Non-unions are classified in two categories: hypertrophic and 
atrophic. Hypertrophic non-unions show signs of callus formation and biological activity in the 
fracture space and occur due to failure to adequately stabilize the fracture. Because hypertrophic 
non-unions show biological activity, they can be remediated by reducing the motion at the fracture 
site through improved fixation. Atrophic fractures, however, occur due to a lack of biological 
activity [5]. Particularly in the case of atrophic non-unions, bone healing fails due to a lack of 
adequate vascularization and biological activity of bone-forming cells [9].  
1.2.1 Current Techniques to Stimulate Bone Healing 
Current methods of addressing atrophic non-unions include the application of autologous, 
allogeneic, or synthetic bone grafting material, nail exchange surgical revisions, as well as less 
invasive techniques, such as electrostimulation. The use of these methods depends on the type of 
fracture, its anatomical location, and previous techniques applied.  
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1.2.1.1 Nail Exchange Surgical Revisions 
Nail exchange surgical revisions are applicable to fractures that have been previously addressed 
with the insertion of an intramedullary nail, typically in the femoral and tibial diaphysis [10-12]. 
The nail exchange method involves removing the current intramedullary nail, reaming and 
enlargement of the medullary canal, and the insertion of a larger nail, which may have an increase 
of 1-4mm in diameter over the original nail [10-12]. This method is effective for addressing both 
hypertrophic and atrophic non-unions, as it addresses the underlying causes of both non-union 
types [10]. In the case of hypertrophic non-union, the insertion of a larger nail mechanically 
stabilizes the fracture, whereas in the case of atrophic non-union, the reaming of the intramedullary 
canal increases blood flow, bringing circulating cells to the wound space and stimulating biological 
healing [10]. Additionally, nail exchange revisions are theorized to promote healing due to 
increased load or compression across the fracture site, or dynamization [25]. Although nail 
exchange surgical revisions have been shown to be very effective in achieving union in the femoral 
and tibial shafts, this method is limited to those anatomical locations, and is not recommended in 
the case of comminuted fractures.  
1.2.1.2 Electrostimulation 
Electrostimulation, a method for stimulating bone healing that gained popularity in the 1950s, can 
be categorized into three main techniques: direct electric current, capacitive coupling, and 
inductive coupling [13, 14]. Stimulation via direct electric current is the most invasive of the 
techniques, delivering an electric field via cathode implantation at the site of the fracture [4, 15]. 
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In contrast, capacitive coupling and inductive coupling are both non-invasive methods that deliver 
electric fields to the fracture through cathodes or coils placed on the skin surface [13, 15]. While 
the cellular mechanisms underlying the efficacy of these methods is not completely understood, 
the primary model supporting electrostimulation is that bone tissue is formed under electronegative 
potentials (and resorbed under electropositive potentials) [13]. Relating this concept to mechanical 
forces on bones, compression generates electronegative potentials, causing bone formation (while 
tension generates electropositive forces) [13]. Because fractured bones should generally not be 
subject to mechanical forces, particularly during early healing stages, electrostimulation may be a 
way to bypass mechanical stresses while still delivering bone-forming electric potentials. Studies 
of non-invasive capacitive and inductive coupling techniques have shown the upregulation of 
intracellular calcium production, extracellular matrix proteins, as well as increased production of 
bone morphogenetic protein (BMP) mRNA [4, 13]. However, electrostimulation currently delivers 
mixed clinical results [14], which may be, in part, due to a lack of standard dosage (electrical field 
strength) and configuration of the field over the fracture space [13, 14]. 
1.2.1.3 Autografts and Allografts 
Autografts are bone tissues taken from the patient’s own body at a separate location from the 
fracture, typically harvested from the iliac crest [16]. Autografts are the gold-standard grafting 
material, as they are osteogenic (contain osteoblasts or osteoblast precursors) osteoconductive 
(meaning that it provides a viable matrix to facilitate new bone growth) and even osteoinductive 
(meaning that it will recruit and differentiate mesenchymal stem cells into new bone tissue) [17, 
18]. Autografts may consist of either cortical or cancellous bone [16], which each have benefits 
and drawbacks; cancellous autografts will be easily revascularized, but provide minor structural 
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support, while cortical autografts initially provide structural strength, but are slower to become 
revascularized and resorbed [19]. However, autografts still have several drawbacks: because they 
are harvested from a separate site from the fracture, obtaining autograft material requires a 
secondary surgical site, which increases operating time and the chances of infection. Additionally, 
the quantity and quality of autografts may be less than sufficient, depending on patient physiology 
[19].  
Allografts, harvested from donor sources, are typically frozen, freeze-dried, or 
demineralized before use as a graft [16]. Therefore, the harvesting, processing and storage methods 
weigh heavily on the efficacy of allograft material. Under ideal conditions, however, allograft 
material may still be moderately osteoinductive [16]. Because allografting material may be 
harvested from a single donor, or aggregated from multiple donors, the biological capacity is also 
variable and influenced by the source [16, 19]. While allografts overcome some of the issues 
associated with autografting, such as secondary surgical sites and limited graft quantity, they 
present problems of their own. For example, because allografts are not derived from the recipient, 
there is a chance that the graft will be immunologically incompatible, and subsequently, prevent 
revascularization and bone formation, or even be rejected [16]. Additionally, allografts are 
associated with a higher incidence of delayed union or nonunion in comparison to autografts [16]. 
1.2.1.4 Synthetic Scaffolding and BMP-2 Therapy 
As an alternative to autografts and allografts, synthetic grafting materials offer several benefits, 
such as eliminating the need for a secondary surgical site to harvest bone material (in the case of 
autografting) and reduction of the likelihood for an immunogenic response or rejection (in the case 
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of allografting). Currently available for clinical surgical repair are a class of calcium phosphate 
ceramics, which are available in several forms, including granules, non-porous blocks, and porous 
blocks [19]. Calcium phosphates are a promising biomaterial for bone repair, as these materials do 
not elicit a foreign body response, and can be either resorbed or converted into hydroxyapatite in 
the body [19]. Also available for clinical use is a combination graft, comprised of calcium 
phosphate, hydroxyapatite, collagen, and autologous bone marrow. These grafts are advantageous 
for bone repair because they serve not only as an osteoconductive material, but also include 
osteoprogenitor cells and osteoinductive growth factors from the incorporated bone marrow [19]. 
As an alternative to using autologous bone marrow in combination with synthetic scaffolds to 
provide a source of growth factors (which requires a second surgical site), bone grafting substitutes 
have been developed that include recombinant human BMP-2 (rhBMP-2) [20], which is produced 
ex vivo in a laboratory setting. Typically administered via collagen sponge to enhance bone repair, 
the administration supplemental BMP-2 in vitro and in vivo has been shown to aid in the 
proliferation and differentiation of pre-osteoblastic cells [21]. rhBMP-2 therapies initially gained 
FDA-approval in 2002 for lumbar spinal repair, and have since expanded to be FDA-approved for 
use in tibial fracture healing [22-24] and to include several applications for rhBMP-7.   
While the inclusion of recombinant BMPs in synthetic scaffolding have been shown to be 
clinically viable options for fracture repair, several drawbacks are associated with this treatment. 
One of the dominant issues with in vivo BMP delivery is the overproduction of bone tissue, 
sometimes in nearby, dissimilar tissues (ectopic bone formation) which in spinal repair, may cause 
the undesirable complete fusion of vertebrae [26, 27]. BMPs are also currently delivered in dosages 
nearly a million times greater than physiological concentrations [20], making treatments costly 
and increasing the likelihood for ectopic bone formation. For these reasons, several methods of 
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more effectively delivering BMPs, have been explored, such as its encapsulation in natural and 
synthetic polymers [28]. 
Figure 2. Examples and illustrations of current fracture healing techniques, including: A) 
intramedullary nail insertion [1], B) electrostimulation [29], C) autograft harvesting for 
implantation [1], and D) preparation of synthetic scaffolding with rhBMP-2 for implantation [30]. 
1.3 CURRENT CHALLENGES IN BONE HEALING 
To address the occurrence of non-unions in fracture healing, there exist several diverse, clinically-
approved option, including nail exchange surgical revisions, non-invasive electrostimulation, the 
placement of auto- or allografts, and synthetic scaffolding materials, that may or may not include 
supplemental rhBMP-2. For treating atrophic non-unions, it is important to select a treatment 
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option that will stimulate biological healing, as atrophic non-unions are characterized by a lack of 
observable biological activity, due to an absence of adequate vascularization and activity of bone-
forming cells [9].  
To overcome this lack of biological healing and enhance bone repair, supplemental 
rhBMP-2 may be administered to aid in the proliferation and differentiation of pre-osteoblastic 
cells [31]. However, in addition to osteoblast-driven bone matrix formation and mineralization, 
bone fracture healing and repair is widely recognized as a complex, multi-stage process of 
restorative steps [17, 25, 26]. During successful bone healing, revascularization of the wound space 
first occurs (angiogenesis), followed by either cartilaginous callus formation or primary bone 
healing (osteogenesis) [5, 17]. While osteogenesis is enhanced by the addition of BMP-2, 
angiogenesis is also a critical stage of bone healing, may not be adequately enhanced with BMP-
2 treatment alone [27]. Importantly, angiogenesis plays a significant role in bone repair, as newly 
formed vessels provide critical supply of nutrients, waste removal, and promotion of cell migration 
into the bone regenerating niche [28]. Without substantial angiogenesis, bone grafts necrose and 
ultimately fail [32, 33]. Additionally, it has been shown that particular anatomical locations, such 
as the distal tibia, femoral head, and talus have an extremely poor chance of healing due to the 
likelihood of the disruption of angiogenic supply from surrounding tissue [29-31].  
While the administration of rhBMP-2 has been shown effective in upregulating bone repair 
via osteoblast proliferation and differentiation [31], the clinical efficacy of growth factor 
administration as a fracture repair therapy may be advanced if rhBMP-2 is delivered with growth 
factors that also upregulate the critical stage of angiogenesis. Additionally, if these growth factors 
could be delivered with greater control, dosages closer to physiological concentration could be 
used in these therapies, lowering their cost and preventing unwanted overproduction of targeted 
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tissues. To achieve this, however, requires the identification of (at minimum) an angiogenic and 
osteogenic growth factor, an understanding of how these growth factors function in situ in the bone 
regeneration niche, as well as their potential interactions with cells and each other. 
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2.0 GROWTH FACTORS IN BONE HEALING 
Growth factors exert influence over more than one biological process during regeneration. For 
example, beyond the most commonly recognized roles of BMP-2 (discussed below), this signal 
also appears to play a role in regulating angiogenesis [34-36]. In fact, earlier studies indicate that 
multiple forms of BMP (in part) promote angiogenesis by inducing the secretion of VEGF-A from 
preosteoblastic cells [36]. Yet, notably, a more recent investigation of BMP effects on 
angiogenesis suggests that depending on the form of BMP and its physiological setting, either a 
pro- or anti-angiogenic effect may be observed [34]. Furthermore, it has been shown that certain 
BMPs may have either a pro- or anti-angiogenic effect depending on the type of endothelial cell 
targeted [35].  
BMP is not the only growth factor that exhibits multiple functions within the regenerating 
niche. Other common growth factors used for bone regeneration, including VEGF, PDGF, and 
FGF, have all been demonstrated to provide different instructions to different cell types (Fig. 3). 
For instance, studies suggest that FGF not only plays a role in upregulating bone formation by 
promoting osteoblast proliferation (and possible differentiation) via multiple signaling pathways 
[37], but it also has a well-recognized influence on endothelial cells, promoting angiogenesis [38, 
39]. Similarly, although VEGF is typically associated with the upregulation of angiogenesis, it 
also plays a part in ossification and can affect bone formation by attracting mesenchymal stem 
cells (MSCs) and promoting their differentiation towards an osteoblastic phenotype [40]. PDGF, 
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another growth factor typically known for its role in regulating angiogenesis through the 
stimulation of VEGF production [41] and the recruitment of stabilizing mural cells [42, 43], also 
acts as a chemoattractant and mitogen for MSCs [44] (Fig. 3). Overall, it can be concluded that 
growth factors generally are not limited to a single function, but rather, are each activating multiple 
signaling pathways that may drive (or inhibit) regeneration [45]. 
2.1 BMP-2 FOR BONE FORMATION 
BMP-2 has been frequently incorporated in scaffolds for bone regeneration because of its well-
recognized ability to promote bone formation [46, 47]. At the cellular level, BMP-2 is a potent 
inducer of osteoblast proliferation as well as a differentiator of mesenchymal stem cells towards 
an osteoblastic phenotype [48] (Fig 3). Accordingly, BMP-2 increases bone formation at the defect 
site for applications ranging from spinal fusion [49] to dental and craniofacial regeneration [50]. 
While these studies are evidence of the usefulness of BMP-2 for inducing mineralized tissue, there 
are large variations in the success of human response to BMP-2 treatment.  For example, in one 
clinical investigation, stimulation of bone regeneration stimulation following administration of 
BMP-2-soaked collagen sheets ranged from excellent bone formation, to no bone formation with 
fibrous tissue in patients receiving the same delivery construct [51]. This may be explained by the 
rapid delivery of BMP-2 from collagen-soaked scaffolds, mediated primarily by protein 
desorption, with no barriers to diffusion to create sustained release rates [52]. As noted in other 
studies, when BMP-2 (or other growth factors) are delivered via bolus administration, they rapidly 
diffuse from the site of administration with a lack of temporal and spatial control, resulting in only 
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transient cellular stimulation with supra-physiological concentrations of the growth factor[53] . In 
an attempt to present proteins in a more physiologically relevant manner, several methods to 
sustain BMP-2 release have been explored, including its encapsulation within (and release from) 
polymers, its expression through delivery of plasmids, and its entrapment within scaffold coatings 
[54-56]. While basic sustained release provides a more extended signal to cells to direct bone 
regeneration, a major shortcoming of delivering only BMP-2 is the limited capacity for BMP-2 
alone to initiate vascular network formation [57]. As previously described, vascular infiltration is 
a required and necessary phase of overall bone healing that precedes ossification [17, 58]. Hence, 
in addition to (and, in the context of vascularization, more significantly than) BMP-2, delivery of 
several known angiogenic growth factors have also been explored during bone regeneration to 
promote vessel development and growth 
2.2 ANGIOGENIC GROWTH FACTORS 
Angiogenic factors include (amongst others) VEGF, a potent mitogen for endothelial cells [40], 
and platelet endothelial growth factor (PDGF), which has been shown to act as a chemoattractant 
for cell types that stabilize growing vasculature [43, 59] (Fig. 3). Moreover, PDGF has also been 
observed to upregulate VEGF production for continued angiogenesis [44]. Beyond VEGF and 
PDGF, additional angiogenic factors observed in the bone regeneration niche include fibroblast 
growth factor (FGF), which plays a role in the sprouting of new capillaries [39], and insulin like 
growth factor (IGF) a growth factor known to play a role in adult neoangiogenesis [58]. Each of 
these angiogenic factors have also been delivered to enhance bone healing and, specifically, the 
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vascularization stage of regeneration. Notably, several studies suggest that delivering angiogenic 
factors alone for bone regeneration leads to the inability to produce organized bone regeneration 
[57, 60, 61]. Indeed, when releasing VEGF alone, no bone formation was observed in either 
ectopically or orthotopically implanted scaffolds. [57]. These results are in agreement with the 
building body of evidence suggesting that the delivery of a single growth factor is oversimplifying 
the regenerative process [59]. At the same time, when delivering multiple growth factors, we must 
understand their role in the regenerative niche to properly coordinate their spatiotemporal 
presentation [62].  
2.3 GROWTH FACTOR ROLES IN THE REGENERATIVE NICHE 
Growth factors exert influence over more than one biological process during regeneration. For 
example, beyond the most commonly recognized roles of BMP-2 (discussed above), this signal 
also appears to play a role in regulating angiogenesis [34-36]. In fact, earlier studies indicate that 
multiple forms of BMP promote angiogenesis by inducing the secretion of VEGF-A from 
preosteoblastic cells [36]. Yet, notably, a more recent investigation of BMP effects on 
angiogenesis suggests that depending on the form of BMP and its physiological setting, either a 
pro- or anti-angiogenic effect may be observed [34]. Furthermore, it has been shown that certain 
BMPs may have either a pro- or anti-angiogenic effect depending on the type of endothelial cell 
targeted [35].   
In addition to BMP, several other growth factors, including VEGF, PDGF, and FGF have 
been found to stimulate stages of bone regeneration [37-39]. Interestingly, these growth factors 
have been shown to play several roles, acting on multiple cell types. For example, PDGF has been 
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shown to both promote angiogenesis, and also acts as a powerful mitogen for (pre-osteoblast) 
MSCs [41, 44]. In Table 1, these signaling pathways are summarized to highlight the various roles 
that growth factors may play across multiple phases of bone regeneration. 
Table 1. Common Growth Factors and their Roles in the Bone Regeneration Niche 
Growth 
Factor 
Roles in Bone Regeneration Cell Types Involved 
BMP-2 1. Differentiates osteoprogenitors to osteoblast cell type
[51]
2. Upregulates osteoblast proliferation [51]
3. May promote or antagonize angiogenesis [34]
Secreted by vascular and mesenchymal stem cells 
[63]; acts on osteoprogenitors and osteoblasts 
[51] 
TGF-β 1. Recruits osteoblast precursors [64, 65] Inactively present in bone matrix until 
proteolytically activated; acts on osteoblast 
precursors [64] 
PDGF 1. Induces proliferation of mesenchymal stem cells [44]
2. Upregulates angiogenesis and VEGF production;
stabilizes newly forming vessels, [44]
3. Induces chemotaxis of mesenchymal stem cells to
support forming vasculature [43, 59]
4. Induces chemotaxis of mesenchymal stem cells to the
bone healing space [66]
Secreted by platelets, neutrophils, and 
macrophages [67]; acts on mesenchymal stem 
cells [43, 44, 59, 66] 
VEGF 1. Upregulates angiogenesis; acts as a potent mitogen
for endothelial cells [40, 68]
2. Chemoattractant for mesenchymal stem cells [40]
Secreted by osteogenic cells and platelets; acts on 
endothelial cells [69] and mesenchymal stem 
cells [40] 
IGF 1. Upregulates angiogenesis; induces adult 
neoangiogenesis [58]
2. Enhances bone matrix synthesis [65]
Bound in bone matrix and secreted by osteocytes 
[65]; acts on preosteoblasts [65] and endothelial 
cells [70] 
FGF 1. Upregulates angiogenesis; induces sprouting of new
capillaries [38, 39]
2. Promotes osteoblast proliferation and differentiation
[37]
Secreted by osteoblasts, macrophages, and 
endothelial cells [65]; acts on mesenchymal stem 
cells, osteoblasts [37], and endothelial cells [38, 
39]
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2.4 GROWTH FACTORS AND CELLULAR CROSSTALK 
In addition to the multiple individual roles of growth factors, there is also evidence that 
presentation of multiple growth factors at the same time can produce varied effects, sometimes 
resulting in a synergistic outcome and other times inhibitory effects that are deleterious for tissue 
formation [65]. As previously described, the combined delivery of VEGF and BMP-2 often results 
in better outcomes in terms of vascularized bone formation [57, 71, 72]. It has been suggested that 
VEGF and BMP-2, function synergistically, activating complex crosstalk and feedback 
mechanisms between growth factors and cell types. As an example, VEGF upregulates 
angiogenesis and, at the same time, signals the recruitment of pre-osteoblast cell types [40]. BMP-
2, in turn, promotes osteoblast proliferation and pre-osteoblast differentiation while also 
instructing osteoblastic cells to release VEGF, creating a cycle of intercellular signaling that 
enhances bone formation [36].  
Although exact molecular mechanisms are not fully elucidated, multiple studies have 
shown that synergistic effects of growth factor combinations are often dependent on dosage and 
timing [65].  For example, in multiple studies investigating the effects of BMP delivered in 
combination with FGF, a range of FGF dosages was delivered with the same amount of BMP, 
allowing observance of FGF dose dependency [65, 73-75]. Interestingly, in each of these studies, 
BMP dosage was maintained constant and the amount of FGF was varied, indicating that the 
synergistic effect may not be a result of individual dosages, but rather it depends on the ratio 
between the amounts of FGF and BMP [65, 73-75]. In all of these studies it was found that the 
BMP/FGF combination was synergistic for bone formation at lower ratios (1:5000-1:125, 
FGF:BMP), but inhibitory at higher ratios (1:50-4:1, FGF:BMP) [73-75]. These observations 
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indicate that delivery of multiple growth factors initiates a very complex set of instructions that 
are dependent on how and when each signal is presented. This needs to be accounted for when 
designing scaffolds for bone regeneration.  
Figure 3. Growth factors signaling: Examples of the action of several prevalent growth factors 
related to vascularized bone regeneration. 
2.5 DUAL GROWTH FACTOR DELIVERY 
To create bone scaffolds with a better likelihood of vascularity, the simultaneous incorporation of 
both an angiogenic factor (to jumpstart vessel formation) and an osteogenic factor (typically BMP-
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2, to induce bone formation) has been explored. A controlled, “dual release” of two growth factors 
at the same time could be argued to be closer to mimicking the natural healing process. There is 
indeed some evidence that the delivery of an osteogenic and angiogenic factor can enhance bone 
formation in some circumstances when compared to the delivery of an osteogenic factor alone [61, 
71]. For example, Huang et al. have shown that the delivery of both VEGF and BMP-2 from 
scaffolding seeded with human bone marrow stromal cells (hBMSCs) resulted in significantly 
greater amounts of bone formation than when BMP-2 was delivered alone from the same 
subcutaneously implanted scaffold at 15 weeks using a murine severe combined 
immunodeficiency model [61]. More recently, Subbiah et al. promoted osteogenesis and 
angiogenesis by delivering BMP-2 in combination with VEGF from a subcutaneous scaffold 
without the addition of seeded cells[71]. In this model, scaffolds delivering both factors appeared 
to promote significantly higher levels of osteocalcin expression as well as significantly deeper 
more dense blood vessel penetration than scaffolds delivering BMP-2 alone [71]. These positive 
results have been observed not only in subcutaneous models, but also in bone defect models. For 
instance, in a study by Ratanavaraporn et al. [76], an ulnar critical size defect model was used to 
investigate the co-delivery of stromal derived factor 1 (SDF-1) and BMP-2 [76]. Although bone 
formation after four weeks was observed in scaffolds releasing BMP-2 alone as well as scaffolds 
releasing both BMP-2 and SDF-1, it was found that a larger area of bone with significantly higher 
bone density formed in scaffolds releasing both growth factors [76]. The authors hypothesized that 
this phenomenon may be due to the synergistic mechanisms of SDF-1 recruitment of 
hematopoietic cells and BMP-2 differentiation of osteoprogenitor cells [76]. In a different study 
by Su et al., BMP-2 was delivered in combination with FGF to rabbit mandibular defects and the 
combined growth factor delivery resulted in significantly higher bone formation compared to the 
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delivery of BMP-2 alone when evaluated at 12 weeks post-implantation [77]. Together, these 
results may indicate that releasing both an angiogenic and an osteogenic factor from scaffolding 
could have the potential to improve bone regeneration outcomes over single growth factor delivery 
in some circumstances. 
Although these results are promising, there are other examples of scaffolds delivering 
multiple growth factors that, in contrast to the studies mentioned above, fail to generate 
significantly improved long-term results. For instance, dual delivery of VEGF and BMP-2 in a 
rabbit femoral defect demonstrated only a weak synergistic effect at earlier time points, whereas 
at later time points, dual growth factor delivery groups were indistinguishable from defects 
receiving BMP-2 alone [78].  A similar study of VEGF and BMP-2 delivery to a rabbit cranial 
defect, revealed a higher volume of bone formation and early defect bridging for dual delivery at 
4 weeks, but no significant differences at 12 weeks between groups delivering dual growth factors 
and only BMP at 12 weeks [60]. These results suggest that, although multiple growth factor release 
may initially lead to increased tissue formation or vascularity, dual (or simultaneous) delivery of 
VEGF and BMP does not always lead to significant overall long-term improvement.   
Importantly, in addition to growth factor choice, another component of experimental design that 
must be considered when comparing outcomes is preclinical animal model selection. In early 
investigational stages, it is generally more feasible and cost effective to employ small mammal 
models (mouse, rat, etc.) [79]. Using these models, general effects of growth factors may be 
observed using a subcutaneous design (ectopic implant), but more relevant data may be collected 
from in situ implantation in long bones or craniofacial defects (orthotopic implant) [79]. When 
delivering growth factors in combination with human stem cells or other human tissue, it may be 
necessary to use an immunocompromised animal model to avoid adverse immunogenic results 
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[80]. In this instance the greater biosimilarity achieved using human cells/tissues might be partially 
discounted by an incomplete biological response of the immunocompromised animal. In general, 
while convenient from multiple point of views, small animal models have drawbacks that may 
influence experimental outcomes. For example, rodent and rabbit bone composition share few 
similarities with human bone [79, 81]. After data collection and proof-of-concept in smaller animal 
models, translational studies may progress to larger animal models (canine, sheep, goats, etc.) to 
more closely replicate the human bone healing process [81]. 
2.6 MULTIPLE GROWTH FACTOR DELIVERY AND TIMING 
The combined evidence of the multiple roles that each growth factor can play within the 
regeneration niche and the complex cross-talk between growth factors and major cell types would 
suggest that simple scaffolds do not currently capture the intricacy of the natural healing process. 
In particular, it has been observed that the large number of growth factors that are secreted in the 
in vivo bone healing microenvironment are not presented simultaneously, rather, they are presented 
in a cascading fashion to coordinate the stages of bone regeneration [69, 82]. In fact, the ordered 
presence and absence of growth factors appears to correspond with different stages of regeneration 
[83, 84]. These observations may provide clues as to why single factor or multiple factor delivery 
together may not always achieve the desired outcomes. It may also provide clues as to why the 
simultaneous delivery of two growth factors may or may not achieve a desired outcome. The 
concept of timing in growth factor delivery has been previously investigated in vascular tissue 
regeneration models [38, 59, 85, 86]. For example, in studies performed to observe angiogenesis 
in vivo, it was found that early release of one angiogenic factor (VEGF) in the first 24 hours, and 
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the subsequent release of a second angiogenic factor (SDF-1) from 24-48 hours, significantly 
improved vascularization compared to singular delivery of either growth factors, to their 
simultaneous delivery, or to their delivery in reverse order [85]. These studies suggest that the 
absence of a growth factor at a given stage of regeneration may be just as important as the presence 
of another, illustrating not only the importance of including relevant growth factors in a scaffold, 
but also presenting them in a biologically meaningful order.   
When specifically considering the stages of angiogenesis and osteogenesis during bone 
regeneration, there is evidence that growth factors for each phase have temporal roles and may be 
most effective when delivered in sequence. For example, as described above, PDGF is responsible 
for the recruitment of mesenchymal stem cells and other osteoblastic precursors to the site of bone 
regeneration [87, 88], and it has additionally been shown to upregulate VEGF, in turn, promoting 
blood vessel formation and regulating angiogenesis [44, 89]. Using these observations to inform 
temporal presentation suggests that PDGF release may be effective when restricted to early of bone 
formation (the initial days, possibly up to a few weeks of the regeneration process depending on 
the specific conditions), partly because in fracture healing, the infiltration of vessel networks into 
the healing callus occurs prior to ossification [90]. Importantly, PDGF also upregulates VEGF 
production [88, 89], which if expressed for more than 72 hours, can inhibit maturation of vessel 
networks and produce leaky vessels [91, 92]. Aside from its beneficial effects in recruiting 
osteoblast precursors and upregulating angiogenesis, other studies have shown that for a range of 
PDGF dosages, BMP-induced bone formation was inhibited [65], further supporting the 
hypothesis that some degree of temporal separation may be beneficial for organized regeneration. 
Collectively, these studies suggest that early expression of angiogenic factors during the initial few 
days of regeneration may be advantageous for bone regeneration not only to promote vasculature 
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formation and recruit osteoblast precursors, but also to prevent potentially adverse effects after 
mature vascular networks have been established, such as leaky vasculature and interference with 
tissue mineralization. 
And while it appears that angiogenic factors are most effective when delivered in the early 
days of bone regeneration, studies of BMP delivery suggest that a delayed BMP delivery is likely 
beneficial such that BMP is presented during later stages of bone regeneration, following the 
establishment of a mature vascular network. [63, 93-95].  Specifically, several of these studies 
show that delaying the delivery of BMP for days or weeks after scaffold implantation will generate 
a greater amount of bone formation, presumably by allowing osteoblast precursors the opportunity 
to migrate into the scaffold prior to differentiation [93, 96]. During other types of bone formation, 
particularly distraction osteogenesis (the induction of osteogenesis by the slow, surgical separation 
of bone [97]), BMP was not even expressed until 5 days after distraction in the granulation tissue 
and endothelial cells of the healing microenvironment [63]. Together, results from these studies 
indicate that delayed delivery of BMP-2 from the time of scaffold implantation is recommended 
in order to promote organized bone regeneration.   
With all of these above studies in mind, it must be noted that attempts to truly match the 
intricate orchestration of instructions provided by the body would most likely be time and cost 
prohibitive to translation, as the scalability of fabricating vascularized scaffolds is only now 
starting to be addressed [98]. Furthermore, to ideally direct bone tissue healing as is done naturally, 
each growth factor based “instruction” would need to be administered at just the right time, in just 
the right amount, especially considering crosstalk potential and the stage-wise process of 
angiogenesis and osteogenesis. To balance the feasibility of scaffold production with the 
requirements of generating vascularized bone tissue, it will be important to carefully select only 
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the most necessary “instructions” with only the simplest possible temporal spacing. In the next 
chapter, we explore several design methods for incorporating controlled release growth factors 
into scaffolding constructs that attempt to balance these constraints. 
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3.0 DEVELOPMENT OF SYNTHETIC SCAFFOLDING FOR CONTROLLED 
GROWTH FACTOR DELIVERY 
3.1 POLYMER ENCAPSULATION SCAFFOLDING 
Scaffolds fabricated from synthetic polymers offer a high level of control over material properties 
which play an important role in protein release, such as degradation rates, porosity, and 
microstructure [99]. Various categories of polymers have been used to create scaffolding for 
growth factor delivery, including hydrogels and polyesters [100]. These polymers can be processed 
in a multitude of ways, including casting, crosslinking and gas foaming, to create entire scaffolds 
while encapsulating growth factors for controlled release [99, 100]. In addition, one way of 
delivering multiple growth factors with distinct profiles from a polymeric scaffold is to use a 
combination of polymers in scaffold fabrication. By using polymers with different degradation 
behaviors to separately incorporate growth factors, multiple, distinct release profiles can be 
achieved (Fig. 4). For example, Kanczler et al. were able to release VEGF and BMP-2 from a 
compartmentalized scaffold comprised of alginate and poly-lactic acid (PLA) [72]. By 
incorporating VEGF in the alginate phase, and BMP-2 in the more slowly degrading PLA phase 
of the scaffold (Fig. 4a), independent release kinetics were realized, generating fast VEGF release 
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and slower, more sustained BMP-2 release [72]. Another way of achieving distinct release profiles 
while using a single polymer scaffold is by using differing methods of growth factor incorporation. 
For example, Richardson et al. produced a poly(lactide-co-glycolide) (PLG) scaffold with fast-
releasing VEGF and slow-releasing PDGF for vascular regeneration by using two methods of 
growth factor inclusion [59]: lyophilized VEGF was mixed with PLG particulate, while PDGF 
was encapsulated within PLG microspheres. Both PLG components were then fused to create the 
scaffold, which quickly released VEGF from its surface. PDGF release, on the other hand, was 
dependent on microsphere degradation/erosion rates. Together, these release profiles resulted in 
larger, more mature blood vessels [59]. Microsphere encapsulation has also been successfully used 
to create protein-releasing scaffolds with multiple material phases, that is, microspheres fabricated 
from one polymer and then embedded into a scaffold composed of a second polymer (Fig. 4b). 
Using this approach Basmanav et al. encapsulated BMP-7 and BMP-2 in poly(4-vinyl 
pyridine)/alginate hybrid microspheres, which were then incorporated into a poly(lactic-co-
glycolic) acid (PLGA) foam scaffold [101]. The most striking difference in release profiles was 
the change in the burst release of proteins, achieved by altering the percentage of polymer in the 
microspheres. When modeling release with bovine serum albumin (BSA) as a proof of concept, it 
was found that burst release was reduced with increasing microspheres polymer concentration 
(ranging from 4-10%). Crosslinking temperature was also found to influence release rates; BSA 
release was accelerated for microspheres prepared at lower crosslinking temperatures, likely 
because crosslinking was retarded. In one experimental condition, BMP-2 was released from 
quickly degrading microspheres (4% polymer), and BMP-7 was released from more slowly 
degrading microspheres (10% polymer) to in vitro bone marrow stromal cell cultures. The highest 
alkaline phosphatase (ALP) activity, an indicator of calcification, was observed in scaffolds 
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containing both types of microspheres, when compared to scaffolds releasing either BMP-2 or 
BMP-7 alone [101]. In another instance of using of multiple polymer formulations, Kim et al. 
constructed a chitosan gel scaffold with embedded gelatin microspheres [102]. In this case, to 
create distinct release profiles, insulin growth factor (IGF-1) was encapsulated in the gelatin 
microspheres, whereas BMP-2 was directly mixed into the chitosan gel. This system released 
BMP-2 more quickly and IGF-1 more slowly, resulting in more in vitro ALP production at day 7 
compared to scaffolds releasing BMP-2 alone, and scaffolds releasing both BMP-2 and IGF-1 from 
the gel phase of the scaffolds (no microsphere encapsulation, i.e., no sequential release) [102]. A 
key advantage in using polymer microspheres for protein encapsulation is that recent mathematical 
models have been developed to accurately predict release profiles of individual molecules [103]. 
Predictive modeling is particularly beneficial for the design of controlled release formulations for 
multiple growth factors, since microsphere compositions can be tuned ab initio to produce a pre-
programmed “lag phase,” or phase of delayed release, that allows for the engineering of sequential 
release profiles. In particular, PLGA microspheres can be engineered exploiting these predictive 
methods to preferentially sequester depots of growth factors, delaying their presentation to the 
body by manipulating polymer material properties including molecular weight, co-polymer ratio, 
and microsphere surface porosity [103]. 
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Figure 4. Polymer Encapsulating Scaffolding. Examples of polymer-based encapsulation 
strategies for multiple growth factors based on (a) dual polymer interpenetrating scaffolds [72] or 
on (b) scaffold incorporating growth factor eluting microspheres [59, 101, 102]. 
Although distinct release profiles were achieved using these polymer encapsulation methods, in 
some cases other key material properties, such as osteoconductivity and structural integrity, may 
be compromised when fabricating scaffolding from only synthetic polymers [72]. These additional 
material properties can be rescued by incorporating protein-encapsulating polymeric microspheres 
within another material matrix that is naturally osteoconductive, such as calcium phosphate. 
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Several studies have characterized material properties of composite polymer/calcium phosphate 
scaffolds [104-107], which together can offer the benefits of tunable growth factor delivery 
(endowed by the use of synthetic polymers) with material properties such as high compressive 
strength, osteoconductivity, and biodegradability (endowed by natural ceramics) [82]. In a study 
of scaffold mechanical properties, Link et al. found that calcium phosphate scaffolds with 20% 
weight PLGA microparticles showed increases in shear strength over an 8 week study as a result 
of bone formation within pockets left by degrading polymer microparticles [104]. While still 
mechanically insufficient for load bearing applications, the calcium phosphate scaffold provided 
a structural template and an osteoconductive interface. Additional studies have explored the effects 
of polymer microsphere chemistry on the material properties of composite scaffolding. Differences 
in polymer microsphere charge [108], density (hollow vs. solid) [105], and material composition 
[106] have been shown to influence scaffold degradation rates and subsequent bone ingrowth [105,
108].  Therefore microspheres can be optimized not only to control protein release, but also to 
modulate overall scaffold properties. Several studies have explored release of a single drug or 
protein from such a polymer/ceramic composite scaffold [109, 110]. Combining release profile 
information with material property characterization of the hybrid scaffolding [104-106] shows 
promises for these composites, which could be used as templates for temporal release of multiple 
growth factors while at the same time contributing desirable bone scaffold physical properties.    
Overall, polymer encapsulation methods constitute a versatile platform for growth factor 
delivery. Polymers may be used to create full scaffolds, or fabricated as a secondary construct, 
such as microspheres. Although polymers alone may lack the material properties, such as 
mechanical strength, required for bone engineering, stronger, more osteoconductive materials, 
such as calcium phosphate, may be used in combination with growth factor-releasing polymers to 
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create composite scaffolding. However, the addition of polymer microparticles to calcium 
phosphate may reduce the strength of the scaffold [110]. Furthermore, when secondary materials, 
such as calcium phosphate, are used with controlled release polymer formulations, growth factor 
release is greatly reduced, most likely because released proteins are sequestered by adsorption to 
the material’s surface [110, 111]. For these reasons, secondary materials must be carefully chosen 
to provide structural integrity and osteoconductivity while not overly interfering with growth 
factor release kinetics. An additional consideration when using polymer encapsulation methods 
for controlled protein delivery is the preservation of protein bioactivity. There exist several 
potential mechanisms of protein inactivation; for example, it has been demonstrated that proteins 
encapsulated in PLGA may be irreversibly inactivated due to conditions including elevated 
moisture levels, the acidic microenvironment created via PLGA degradation, adsorption of the 
protein to the polymer surface, or the aggregation of insoluble protein masses [112, 113]. To 
combat these potential sources of protein inactivation, it may be necessary to include additional 
components during the encapsulation process, such as a basic salt to reduce the acidity of the 
microenvironment [113], or even to pre-encapsulate proteins within dextran nanoparticles to 
protect against exposure to solvents and prevent protein aggregation [114].   
3.2 CORE-SHELL SCAFFOLDING 
Another method of fabricating temporally distinct release patterns is the physical separation of 
growth factors using core-shell scaffolds. Specifically, distinct temporal release profiles can be 
achieved through the degradation properties of the core-shell design, in part through the selection 
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of bulk-eroding and surface-eroding materials [115]. Generally, the core-shell scaffold 
arrangement allows for temporal release through its construction of a quickly degrading shell, 
which protects a more slowly degrading core [116]. Using a core-shell approach, Perez et al. 
created a microfibrous scaffold with a concentric injection nozzle, in which each fiber was 
comprised of one phase of pure alginate and a second phase of alginate with α-tri calcium 
phosphate (α-TCP) (Fig. 5a). The protein for delivery, cytochrome C, was loaded into either the 
“core” or “shell” phase of the fiber [117]. Depending on the protein location (core vs shell) and 
the composition of the phase (percentage of α-TCP, of alginate, and amount of crosslinking), 
differing release profiles were generated. It was found that the addition of α-TCP resulted in 
prolonged release profiles with minimized burst release. Furthermore, the release profiles of the 
core-encapsulated protein could be altered either by changing core composition or by varying shell 
composition, because the mechanism for release depends (at least in part) upon diffusion through 
both the core and shell materials [116]. While effective in creating unique release profiles, one of 
the possible limitations of the core-shell fiber design for multiple growth factor release is that 
modulation of release properties requires changing the material properties of the scaffold. In the 
previously described example, release profiles were altered most drastically with the addition of 
α-TCP, which also notably altered the storage and loss moduli of the scaffold [117].  
To avoid the potential pitfall of sacrificing desired material properties to achieve release 
profiles (or vice versa) another approach to the core-shell design can be implemented using a 
secondary material phase to control release of proteins. One approach to creating this design of 
core-shell scaffolding is to first encapsulate growth factors in polymer microparticles that are then 
incorporated in a secondary scaffolding material directly loaded with the second growth factor 
(Fig. 5b). This approach was used by Kempen et al. to release VEGF and BMP-2 [57]. In this 
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study, the microparticles were meant to act as the “core” and the embedding material as the “shell.” 
The use of degradable polymer microparticles allows for a further level of control since they can 
be designed to produce different release profiles independently from the overall scaffold structure. 
To create a sustained BMP-2 release profile, BMP-2 was encapsulated in degradable microspheres 
(composed of PLGA) and then embedded into poly propylene fumarate (PPF) to create the core of 
the scaffold. A gelatin phase into which VEGF was directly incorporated served as the scaffold 
“shell”. It was found that the complete in vitro release of VEGF leveled off within 2 weeks, 
whereas BMP-2 release from the core was sustained for more than 4 weeks. A high burst release 
of VEGF from its hydrogel shell was observed both in vitro and in vivo [57]. Using this core-shell 
approach, Kempen et al. achieved distinct release profiles for BMP-2 and VEGF, which was found 
to enhance ectopic bone formation, as indicated by significantly higher bone volume formation in 
scaffolds releasing combined VEGF and BMP-2 [57].  
In addition to using microspheres as the “core” phase that is then incorporated into a secondary 
“shell” scaffolding material, microspheres that act themselves as core-shell configurations can be 
produced [118-120] (Fig. 5c). The main advantage of this core-shell configuration is that 
microspheres can easily be packed into irregular bone defect shapes, a more difficult feat for 
prefabricated block scaffolding [118]. A recent example is provided by Wang et al. [119] who 
used a PLLA core to encapsulate BMP-2, and a PLGA shell to encapsulate FGF. These core-shell 
microparticles were capable of releasing both growth factors with distinct release profiles and 
could be used without a scaffold to improve fracture healing [119].  
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Figure 5. Core-Shell Scaffolding: Examples of different strategies to obtain a core-shell scaffold, 
by fabricating (a) a growth factor eluting fiber core within a polymeric fiber [116, 117], by (b) 
incorporating growth factor eluting microspheres in a polymer fiber incorporating a second growth 
factor [57], and by (c) creating microspheres with a core that incorporates a first growth factor and 
an outer shell that contains the second growth factor [118-120]. 
Overall, core-shell scaffolding offers the possibility to control the local spatial separation of 
growth factors release [116]. Furthermore, implementation of the core-shell system through the 
incorporation of microparticles may allow for more control over material properties of the 
scaffolding material in which they are embedded, or core-shell microparticles may even be used a 
stand-alone system [118-120]. However, one remaining limitation of this approach is that the shell 
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phase influences release of growth factors incorporated in both the core and shell phases of the 
scaffold. Because the shell is the outermost tier of the scaffold, whether proteins are incorporated 
within the core or shell phase, they must either diffuse through the shell phase or be delayed until 
its erosion [116]. This configuration could even prove advantageous to allow longer term release, 
but must be accounted for when designing core-shell release systems and selecting the core 
material properties.  
3.3 LAYER-BY-LAYER SCAFFOLDING 
Another category of scaffolding architecture for temporal delivery of multiple growth factors is 
layer-by-layer (LbL) scaffolding. Like core-shell scaffolding, LbL scaffolds are created by 
depositing a series of biomaterial sheets or molecular layers, while allowing curing or hardening 
of each layer (if necessary) before the next is placed. Growth factors are thus spatially separates 
into different physical material layers to govern their release, similarly to the separation in core-
shell scaffolding. Although the categories of core-shell and LbL designs may be considered to 
describe somewhat similar scaffolding configurations, in this review, the term “LbL scaffolding” 
will refer to 1) scaffolds composed of two or more side-by-side layers (that are non-concentric), 
or 2) thin layers used to coat a scaffolding material that does that does not have a growth factor-
filled core. 
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Figure 6. Layer-by-Layer Scaffolding: Examples of layer-by-layer scaffolds realized by (a) 
juxtaposing growth factor incorporating polymers with different degrees of crosslinking [121, 
122], or by (b) coating a porous scaffold with a dual polymeric layer containing different growth 
factors [123, 124]. 
One way that LbL scaffolding takes advantage of chemical and material properties to release 
multiple growth factors is by modifying the curing process of each layer to modulate release 
profiles. For example, when using the same polymer to fabricate multiple layers, differing release 
profiles can be achieved by crosslinking to a different degree each layer (Fig. 6a). Raiche and 
Puleo [121] used this method to create a BMP-2 and IGF-1 eluting scaffold consisting of two 
gelatin layers: a “top” layer which was crosslinked to a lesser degree than the second highly-
crosslinked “bottom” gelatin layer When added into the lesser crosslinked layer, BMP-2 release 
was accelerated, with peak release on day 1 and completion of release approximately after 7 days. 
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However, when added to the more highly crosslinked layer, peak BMP-2 release was delayed until 
day 6. Using a similar crosslinking method for LbL fabrication, Kim et al. [122] released IGF-1 
and TGF-β from a oligo(poly(ethylene glycol)fumarate) (OPF) scaffold. While IGF-1 release 
profiles remained constant for all groups, TGF-β release was altered by incorporating it into 
different layers of the scaffolding. Burst release was suppressed through increasing polymer 
crosslinking in the layer impregnated with TGF-β. To even further minimize the burst release of 
TGF-β, the growth factor was first encapsulated into gelatin microspheres before its inclusion in 
the more highly crosslinked layer of the scaffold. Although the TGF-β release profile was 
successfully altered by its incorporation in differing layers and microspheres, increased temporal 
separation of these two growth factors may be required, as better subchondral bone morphology 
was observed in scaffolds delivering IGF-1 alone, indicating potential remaining antagonistic 
growth factor signaling [122]. 
While useful in advancing the LbL technology platform, methods of fabricating an entire 
scaffold in two distinct spatial layers may not be directly applicable in creating a scaffold for 
vascularized bone. Although capable of temporal release of multiple growth factors, if layers 
releasing growth factors are too spatially separated, they may prevent the necessary co-localization 
of vascular and mineralized tissue formation. An alternative approach to the LbL design that may 
offer more co-localized growth factor presentation is to create layered scaffold coatings rather than 
a layered scaffold (Fig. 6b). Shah, et al.[123] adopted this approach to the LbL method to create a 
layered coating for the release of PDGF and BMP-2. Differences in electrostatic attraction between 
each growth factor and polyelectrolyte membranes were exploited to create the “layers” onto a 
PLGA scaffold. The PLGA scaffold was first dipcoated with a layer contained BMP-2, and then 
dipcoated in a second layer containing PDGF, resulting in PDGF releasing more quickly than 
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BMP-2. This temporal release of PDGF and BMP-2 resulted in bone formation with higher 
compressive strength and other mechanical properties that better matched that of native bone as 
compared to scaffolds releasing only BMP-2 [123]. An advantage to this method is the possibility 
for creating a spatio-temporal gradient of growth factors release. As the coatings surface degrade, 
the outer PDGF-laden layer releases its growth factor concentration more quickly, followed later 
by a BMP-2 release. One potential drawback to using the LbL method to generate coatings rather 
than entire scaffolds is that the underlying scaffold material must be carefully chosen and 
fabricated so that cells will be encouraged to completely infiltrated and create tissue after growth 
factor coatings have degraded, particularly if used for filling large defects.  
Similar to core-shell scaffolding, when additional control over protein release is desired, a 
secondary material may be used to first encapsulate the growth factor into microspheres before 
these are added into a layer composed of a different material [122, 125]. A unique advantage of 
the LbL method is that layers can be fabricated more thickly, to create an entire scaffold, or when 
applied more thinly, may be used as a coating. One challenge to the LbL method lies in striking 
the correct balance between layer thickness and spatial growth factor separation. When considering 
LbL applications for vascularized bone, it is important that in the creation of growth factor 
gradients, protein release does not become so spatially separated as to prevent vascularity 
throughout the scaffold. At the same time, when LbL techniques are used to generate thin coatings, 
properties of the underlying scaffold material, such as porosity and osteogenicity, must be selected 
to continue the promotion of tissue formation in the absence of degraded growth factor-laden LbL 
coatings. Additionally, at this time, LbL coatings are capable of generating independent release of 
multiple growth factors but, although release profiles are not identical, they are still simultaneous 
[126]. While the LBL delivery design has been effective for generating more trabecular bone 
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formation over the same scaffolds delivering BMP-2 alone [124], if entirely sequential release 
profiles were to be desired, significant design modification may be required to block interlayer 
diffusion, such as the inclusion of a “barrier” layer to separate growth factor-eluting layers [127, 
128].  
3.4 OTHER GROWTH FACTOR DELIVERY TECHNIQUES 
In addition to the above described synthetic techniques for controlled delivery of soluble growth 
factors, temporal delivery of multiple growth factors is also being addressed using biological 
approaches. Comparison of these methods to those described throughout section 4 are described 
in Table 2. One example of an alternative biological delivery method is the use of platelet rich 
plasma (PRP), which can be derived autologously or allogeneically. Notable growth factors 
present in PRP include IGF, FGF, PDGF, TGF-β, and VEGF [129, 130].  However there appears 
to be great variability in concentrations of these growth factors from donor to donor which 
represents an issue for both clinical application and scientific research [131]. To use PRP as a 
source of delivery for these growth factors in bone regeneration, it is often incorporated into other 
scaffolding material, as (by itself) it lacks the mechanical properties required for load bearing, 
even after activation to form a fibrin matrix to fill local lesions [132-134]. Furthermore, PRP can 
be processed to form a thin membrane [135], which could be used to wrap other scaffold or grafting 
material. While PRP supplies an abundance of growth factors useful for bone regeneration, the 
main hurdle to implementation is the control over the release of each of these growth factors. One 
option pursued by Lu et al. is the incorporation of PRP into different types of alginate carriers, 
which entailed a sustained release of growth factors, and, depending on the carrier fabrication 
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method (internal vs. external gelation), growth factor release, could be delayed for up to 7 days 
[136]. Interestingly, the two growth factors assayed in this study exhibited different release profiles 
when PRP was incorporated into externally gelated carriers, with PDGF release beginning on day 
1, while TGF-β did not release until day 7 [136]. PRP has also been incorporated into various other 
scaffolding materials and designs for delivery to the bone niche, such as nanofibers, sponges, and 
demineralized bone matrix, for more sustained release, but challenges still remain in standardizing 
the amount of active growth factors in each PRP sample [137]. Additionally, it may be difficult to 
finely tune the release of growth factors individually since they are incorporated together, as part 
of the PRP complex into scaffold designs. 
A second, biological alternative for the presentation of growth factor “instructions” is gene 
delivery.  Plasmids (non-viral vectors), as well as adenoviruses, have been used to encode several 
growth factor genes and are incorporated in scaffolding for placement in the bone regeneration 
niche. Some early examples of plasmid use for bone regeneration include the delivery of a BMP-
4 plasmid [138] and parathyroid hormone [139], both of which caused the local and sustained 
expression of growth factors locally (up to 6 weeks). More recently, a plasmid for the expression 
of VEGF was able to sustain transgene expression for 105 days [140]. To achieve sequential or, at 
minimum, temporally separated growth factor expression, adenoviruses have been used in 
combination with other growth factor delivery methods. For example, Luo et al. [141] loaded 
polymer scaffolds with VEGF protein and adenoviruses expressing BMP-2. This delivery method 
resulted in a burst release of VEGF during the first few days of the in vitro release study, and 
sustained BMP-2 expression through day 21. When implanted in vivo, these scaffolds exhibited 
significantly enhanced bone volume formation as well as higher torque values required to remove 
the scaffolds [141]. Although effective in generating greater bone volume [142], growth factor 
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presentation still overlapped to some degree. If greater temporal separation were desired using 
gene therapy, another possible and more sophisticated approach is the inclusion an inducible 
promoter for more control over gene expression [142]. While gene delivery does show promise as 
potential systems for sequential growth factor delivery, there still remain a number of safety 
concerns that could severely limit its clinical implementation [143]. 
Another biological alternative to growth factor delivery (and to growth factor expression 
through gene delivery) is the presentation of small molecules. Unlike proteins, small molecules 
are typically too small (< 1000 Daltons) to induce immunogenic responses, do not require higher-
order structural integrity to maintain bioactivity, and are highly thermally stable [144, 145]. A 
multitude of small molecules that have the potential to stimulate osteogenesis have been identified 
through high-throughput screening methods, several of which have been studied preclinically for 
their efficacy in promoting bone formation in non-unions and long bone fractures [144].  For 
example, simvastatin, a statin traditionally used to combat cholesterol synthesis, was encapsulated 
in PLGA/hydroxyapatite microspheres by Tai et al. [146] to induce bone formation in a mouse 
tibial gap fracture model. In this study, significantly greater callus formation and a significantly 
greater amount of new blood vessel were observed at two and four weeks post-treatment in groups 
receiving simvastatin delivery over control groups. In another study, Monjo et al. [147] delivered 
rosuvastatin from a collagen sponge to rabbit tibial defect and observed significantly higher bone 
density and volume in rosuvastatin treatment groups versus control groups. Both simvastatin and 
rosuvastatin are hypothesized to result in greater bone formation by upregulating osteogenesis via 
the BMP/Smad pathway [144]. Although effective in generating bone formation [146, 147], a 
major challenge in the use of these (and other) small molecules is preventing unwanted effects in 
other cell and tissue types due to nonspecific targeting [144, 145]. To overcome this hurdle, 
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controlled release scaffolding must be designed to deliver small molecules with spatial and 
temporal control to ensure only localized effects to the specific target tissue [144]. 
Table 2. Delivery Method Comparison. Advantages and disadvantages of each delivery method 
Delivery Method Advantages Disadvantages 
Polymer 
Encapsulation 
1. Can be used to make a wide variety of
scaffolding or scaffolding components (ex.
fibers, microspheres, full constructs).
2. Degradation rates and resulting release
profiles are easily manipulated, some of
which can be predicted by mathematical
models.
1. Lack mechanical strength.
2. Lack osteoconductive/
osteoinductive properties.
3. Potential for protein inactivation.
Core-shell Scaffolding 1. Spatially separates growth factors. 1. Core depot release is influenced by
the degradation and/or diffusional
properties of the shell.
Layer-by-layer 
Scaffolding 
1. Spatially separates growth factors.
2. When applied in thin layers (nano-micron
scale), can be used as a coating for other
scaffolding material.
1. Growth factors may be too spatially
separated for adequate bone/vessel
co-localization when thicker layers
are constructed.
2. Interlayer diffusion may occur, the
prevention of which requires
“barrier” layers.
Platelet-rich Plasma 1. Includes many relevant growth factor in
one medium.
1. Great variability in growth factor
concentrations, depending on
harvesting and processing
techniques.
2. Difficult to controllably release
individual growth factors.
Gene Delivery 1. Provides long term local protein
expression.
2. Inclusion of inducible promoters provides
a high level of control over expression.
1. Limited clinical translatability.
Small molecules 1. Does not induce unwanted immune
responses.
2. Highly thermally stable.
3. Bioactivity does not require higher-order
structural integrity.
1. Risk of nonspecific effects on
untargeted tissues
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4.0 DELIVERY OF PDGF AND BMP-2 FOR TUBULE FORMATION AND 
ORGANIZATION 
4.1 INTRODUCTION 
As described in Chapters 1 and 2, a critical challenge to successfully regenerating bone tissue is 
the adequate vascularization of grafts or scaffolding used in repair efforts [148]. As previous 
studies have illustrated, angiogenesis plays a significant role in bone repair, as newly formed 
vessels provide critical supply of nutrients, waste removal, and promotion of cell migration into 
the bone regenerating niche [149].  
While the importance of angiogenesis in bone repair is apparent, the only current FDA-
approved growth factor for addressing poor bone healing is bone morphogeneic protein-2 (BMP-
2), an osteogenic growth factor [46, 150-152]. Though there is some evidence supporting the 
involvement of BMP-2 during angiogenesis [36], it was also demonstrated that BMP-2 delivery 
alone has limited capacity to upregulate vascular formation at the fracture site [57]. Further, BMPs 
have even been shown to inhibit angiogenesis in some situations [34], and antagonisms are known 
to exist between angiogenic growth factors, such as platelet derived growth factor (PDGF), and 
members of transforming growth factor-β (TGF-β) superfamily (including BMP-2) [153]. This 
lack of understanding of the interplay between BMP-2 and angiogenic growth factors may explain 
43 
the inconsistent results of those studying combined delivery of angiogenic growth factors (such as 
VEGF, PDGF, IGF, etc.) with BMP-2 [82, 154].  
Taking clues from studies reporting that bone fracture healing is a complex, multi-stage 
process of restorative steps [17, 90, 155], we hypothesize that the ordered presentation angiogenic 
and osteogenic growth factors will influence angiogenic network formation. Notably, the role, if 
any, of additional parameters of growth factor presentation, including length of delivery and degree 
of overlap, has yet to be fully explored for angiogenesis during bone tissue regeneration.  
The resulting effects of order and spacing of multiple growth factor timing and overlap 
may help guide the development of biomimetic therapeutics, including controlled release systems 
for temporal or spatiotemporal separation of growth factors [102, 119, 121]. To gain further 
information regarding the effects of variation in growth factor presentation for upregulating 
angiogenesis in bone repair, we developed a new in vitro Matrigel plug model assay to assess 
tubule formation in response to various growth factor delivery schemes. While Matrigel is known 
to intrinsically contain low levels of present growth factors [156], it was chosen for use as a three-
dimensional substrate in this application as it is a preferable matrix for assaying the activity of 
endothelial cells and allowing in vitro tubule formation [157, 158]. Because of the background 
levels of growth factors innately present in Matrigel, control groups of cells receiving no additional 
delivered growth factor were included in experimental set-ups to evaluate base levels of tubule 
formation in Matrigel matrices alone. A co-culture of human umbilical vascular endothelial cells 
(HUVECs) and human mesenchymal stem cells (hMSCs) allows for the exploration of both 
angiogenic (organization of HUVECs) and osteogenic (differentiation of hMSCs towards an 
osteogenic phenotype) responses to growth factor treatment groups. HUVECs were chosen for this 
study as they are traditionally one of the most commonly used cell type for in vitro angiogenesis 
44 
assays [159, 160]. However, we also acknowledge that while HUVECs can be used to model 
angiogenic responses, these cells are derived from a different lineage and may exhibit differing 
properties in comparison to the microvascular endothelial cells that would more commonly be 
found in the bone regeneration niche [161-163]. In addition to tubule formation by HUVECs, 
hMSCs have the potential to differentiate into mural cells that support the maturation of newly 
formed tubules [164]. Using the HUVEC/hMSC co-culture in this Matrigel plug assay, we are able 
to assess cellular responses to length, sequence, and degree of overlap in growth factor delivery. 
We have used this model to investigate our hypothesis that the sequence and degree of overlap in 
PDGF and BMP-2 delivery will impact tubule formation in the context of bone repair, as previous 
studies have shown the importance of growth factor sequence regarding angiogenesis alone [38, 
85]. 
4.2 MATERIALS AND METHODS 
A three-dimensional in vitro Matrigel plug was used as a model to explore delivery patterns of 
platelet derived growth factor (PDGF) and bone morphogenetic protein (BMP-2) to a co-culture 
of human mesenchymal and endothelial cells. In the following experiments, we observed how 
various presentation schedules of PDGF and BMP-2 influenced microtubule formation by human 
mesenchymal stem cells and human umbilical vascular endothelial cells.  We assayed for tubule 
formation in response to sequence of growth factor deliver, growth factor delivery timing, dosage, 
and overlap. 
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4.2.1 Tubule Development Assay 
Well inserts of a 24-well transwell plate (Sigma Aldrich) were filled with 250 μL of growth factor 
reduced, phenol-free Matrigel (LDEV free, Fisher Scientific).  Human umbilical vascular 
endothelial cells (HUVECs, Lonza) and human bone marrow-derived mesenchymal stem cells 
(hMSCs, Life Technologies) were seeded at a density of 1.5 x 105 cells per well, in a 1:1 (hMSC : 
HUVEC) ratio.  The lower reservoirs of MSC-HUVEC co-cultures we filled with 500 μL of a 1:1 
ratio of endothelial basal media and minimum essential media (Life Technologies) supplemented 
with 1% penicillin-streptomycin and 1% antibiotic-antimycotic to provide hydration to Matrigel 
plugs. 
4.2.2 Growth Factor Delivery to Cell Cultures 
Growth factor enriched media was prepared by combining endothelial basal media and minimum 
essential media in a 1:1 ratio, and supplementing it 1% penicillin-streptomycin and 1% antibiotic-
antimycotic. For PDGF treatment groups, soluble PDGF-BB (Fisher Scientific) was added to the 
media for a final concentration of 10 ng/mL PDGF.  For BMP treatment groups, soluble BMP-2 
(Fisher Scientific) was added to the media for a final concentration of 100 ng/mL BMP, and for 
PDGF + BMP treatment groups, PDGF and BMP were added to the media for a final concentration 
of 10 ng/mL and 100 ng/mL, respectively. Growth factor concentrations were chosen based on 
dose-dependency studies found in literature references [165, 166]. Based on these studies, the 
lowest dose for which a cellular response was observed was chosen for use in this study. Prepared 
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media was delivered to corresponding groups by injecting 20 μL aliquots per well per day for the 
duration of the experiment. PDGF and BMP were each delivered for a minimum of one day, to a 
maximum of 10 days, with between 0-10 days of overlap, depending on the conditions studied. 
4.2.3 Immunofluorescence 
At the conclusion of the experimental timeframe (10 days) Matrigel plugs were removed from 
transwell inserts, embedded in TissueTek (Fisher Scientific) and snap frozen in liquid nitrogen. 
Frozen sections (10 μm) were incubated with primary antibody mouse anti-human CD31/PECAM-
1 (R&D Systems) and secondary antibody donkey anti-mouse IgG (R&D Systems) to identify 
endothelial cell activity and vessel formation.  Images of CD31-stained sections were taken at 20X 
and 10X using a Nikon inverted light microscope, then analyzed using WimTube software 
(Wimasis Image Analysis, GmbH). 10X images were used for analysis to gain a larger 
representative sample area.  WIMASIS software was used for analysis of four parameters for every 
image: total area covered by vessels, total length of vessels, number of branching points, and 
number of closed loops. These parameters were measured for each representative area imaged at 
10X magnification, and are illustrated in more detail in Supplementary Figure 7.  
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Figure 7. Legend demonstrating quantification parameters (area coverage, tubule length, 
branching points, closed loops) used in this study, and how they are represented in the Wimasis 
software processing system. 
To assay for the potential of MSC differentiation towards a pericyte phenotype when exploring 
length of PDGF delivery, slides were incubated with primary antibody rabbit anti-alpha smooth 
muscle actin (ab5694, Abcam) and secondary antibody goat anti-rabbit IgG H&L (Alexa Fluor 
488, Abcam). Images of slides were taken at 20X using a Nikon inverted light microscope. Alpha-
smooth muscle actin (α-SMA) staining was quantified by analyzing fluorescent intensity of the 
resulting using ImageJ software. Image files were converted to 8-bit formatting, then automatically 
thresholded using the triangle thresholding method in ImageJ. Resulting binary images were 
quantified with the ImageJ “analyze particles” method with default settings.  
48 
4.2.4 PCR for Expression of Collagen-1 
RNA was extracted from Matrigel plugs using an RNeasy mini kit (Qiagen Inc.) following the 
manufacturer’s instructions. Extracted RNA samples were then concentrated using an RNA Clean 
& Concentrator-5 kit (The Epigenetics Company, Zymo Research.) Concentration and quality of 
RNA samples was verified using a NanoDrop analyzer (ThermoFisher Scientific). Real time 
quantitative PCR was then performed using a StepOne Real Time PCR system and software (V2.3) 
(ThermoFisher Scientific). TaqMan inventoried probes and primers (Invitrogen) were used in the 
mRNA analysis. Results, represented as relative level of gene expression, were calculated using 
the threshold cycle (Ct) method and comparative Ct (2-ΔΔCt) calculation. These calculations were 
performed using eukaryotic 18S expression as the endogenous control, and the BMP-2 
experimental group as the reference sample.  
4.2.5 Statistical analysis 
Multivariate ANOVA was performed using GraphPad 5.0 software to identify statistically 
significant differences (p less than 0.05) across multiple experimental groups for each set of in 
vitro growth factor delivery data. Post-hoc multiple comparison testing was performed to compare 
means using Tukey’s test.  Each experimental growth factor delivery group (PDGF, BMP, PDGF 
+ BMP, etc.) contained N=3 samples. For every N, measured outcomes of n=3 cryoslices were
first averaged to better represent each sample. 
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4.3 RESULTS 
Using a three-dimensional in vitro Matrigel plug model, we observed how various presentation 
schedules of PDGF and BMP-2 influenced microtubule formation by human mesenchymal stem 
cells and human umbilical vascular endothelial cells.  We observed that sequential presentation of 
PDGF to BMP-2 led to increased tubule formation over simultaneous delivery of these growth 
factors. Importantly, a 2-4 day overlap in the sequential presentation of PDGF and BMP-2 
increased tubule formation as compared to groups with zero or complete growth factor overlap, 
suggesting that a moderate amount of angiogenic and osteogenic growth factor overlap may be 
beneficial for processes associated with angiogenesis. 
4.3.1 Tubule Formation in Response to Sequential Treatment Schedules 
In order to explore the variable space related to the sequence of PDGF/BMP for induction of 
vascular structures, we explored the growth factor delivery of (1) PDGF alone, (2) BMP alone, (3) 
PDGF + BMP [10 days of PDGF and BMP together], (4) PDGF to BMP [5 days of PDGF alone, 
followed by 5 days of BMP alone], (5) BMP to PDGF [5 days of BMP alone followed by 5 days 
of PDGF alone], (6) “blank” media with no added growth factors (Figure 8). The “blank” 
experimental group, which was supplemented with neither PDGF or BMP, served as a negative 
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control. All growth factor delivery schedules were assayed using the HUVEC/hMSC co-cultures 
seeded in Matrigel plugs. As a baseline, CD31 staining of Matrigel sections revealed at least some 
degree of tubule formation in each experimental group (Figure 9). The greatest amount of CD31 
staining, as quantified by tubule area coverage and tubule length, was observed in samples treated 
with PDGF alone (Figure 10). However, CD31 staining also showed that the sequential delivery 
of PDGF to BMP outperformed other treatment groups in terms of tubule density (quantified by 
area coverage and tubule length per frame) and tubule organization (quantified by number of 
branching points.)  
Figure 8. Sequential growth factor delivery regimens showing type of growth factor delivery per 
day over 10 days. Growth factors were delivered by pipetting 20 μL of media with concentrations 
of 10 ng/mL PDGF and/or 100 ng/mL BMP. 
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Figure 9. Sequential delivery of PDGF to BMP and delivery of PDGF alone results in organized 
tubule formation in vitro. A) CD31 staining of growth factor delivery groups, and B) software 
analysis overlay of the same images, showing quantification methods for tubule area, tubule 
length, branching points, and loops. All scale bars = 50 μm. 
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Figure 10.  Quantification of tubule area, tubule length, branches, and loops for sequential growth 
factor delivery groups showing that PDGF delivery alone (positive control) results in significantly 
greater tubule formation when compared to all other treatment groups at each parameter. 
Sequential PDGF to BMP delivery results in significantly greater tubule area coverage, tubule 
length and branching points when compared to several other treatment groups. # indicates 
significant difference from PDGF to BMP treatment group, * indicates significant difference from 
PDGF treatment group.(ANOVA followed by post-hoc multiple comparison testing using Tukey’s 
test. Α=0.05. 
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4.3.2 Tubule Formation in Response to Length of PDGF Delivery 
Three-dimensional Matrigel plugs in transwell plate inserts were seeded with a 1:1 co-culture of 
hMSCs and HUVECs to evaluate tubule formation and α-SMA expression in response to various 
lengths of PDGF delivery when sequentially delivering PDGF and BMP-2. Within the 10-day 
experimental timeframe, we explored 5 variations in length of PDGF to BMP delivery, with the 
sequential switch occurring after 1, 3, 5, 7, or 9 days of PDGF delivery (Figure 11). Matrigel 
sections treated with longer PDGF delivery before the switch to BMP-2 exhibited greater amounts 
of tubule formation (CD31 staining) and a-SMA expression (Figure 11). As shown in Figure 11, 
when PDGF was delivered for 7 days before the switch to BMP-2, sections of Matrigel plugs 
displayed significantly more a-SMA expression as compared to 1, 3, and 5 days of PDGF delivery. 
When PDGF was delivered for 9 days before the switch to BMP-2, significantly more a-SMA 
staining was observed as compared to 1, and 3 days of PDGF delivery. Greater amounts of CD31 
staining were also observed for 9 days of PDGF delivery as compared to 1, 3, and 5 days. Although 
tubule lumens were not specifically assayed for in this study, they can be longitudinally observed 
in “7 days PDGF/3 days BMP” and “9 days PDGF/1 day BMP” frames of Figure 11, and are 
similar in appearance to longitudinally oriented tubule lumens in similar 3D in vitro studies [167, 
168]. 
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Figure 11. Immunofluorescent staining of CD31 (red), α-SMA (green), and nuclei (blue) of 
matrigel cross sections suggest that longer PDGF delivery before switch to BMP (7 days, 9 days) 
results in greater amounts of tubule formation and presence of pericytes * indicates significantly 
more area coverage vs. days 1,3 and 5. # indicates significantly more area coverage vs. days, 1,3 
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when compared using ANOVA and Tukey’s test for post-hoc comparisons, α = 0.05. All scale 
bars = 50 μm.   
Figure 12. Independent channels for DAPI, CD31 and a-SMA staining for the formation of tubules 
in response to length of PDGF delivery (merge images comprise Figure 11.) 
4.3.3 Tubule Formation in Response to Growth Factor Delivery Overlap 
Three-dimensional plugs of Matrigel in transwell plate inserts were seeded with a 1:1 co-culture 
of hMSCs and HUVECs to evaluate tubule formation in response to treatment groups representing 
various degrees of growth factor presentation overlap in vitro over the 10 day experimental 
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timeframe.  CD31 staining of Matrigel sections revealed that the greatest amount of tubule 
formation occurred in groups with moderate growth factor overlap (2-4 days of overlap) as shown 
in Figure 14. In sections representing 4 days of growth factor overlap, a significantly higher 
amount of tubules (tubule area, length) and greater level of tubule organization (loops, branching 
points) was observed than in any other experimental group (Figure 14). Sections representing 2 
days of overlap were observed to have significantly more tubule area coverage and length than 
sections representing longer periods of growth factor overlap (8 and 10 days). For purposes of 
comparison, the 0-day overlap group in Figure 13 corresponds to the same treatment schedule as 
the “PDGF to BMP” group in Figure 9, and the 10-day overlap group corresponds to the same 
treatment schedule as the “PDGF + BMP” group in Figure 9.   
Figure 13. Overlapping growth factor delivery regimens showing type of growth factor delivery 
per day over 10 days. Growth factors were delivered by pipetting 20 μL of media with 
concentrations of 10 ng/mL PDGF and/or 100 ng/mL BMP. 
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Figure 14. Moderate overlap (2-4 days) in PDGF and BMP delivery results in greater tubule 
formation (CD31 staining). All scale bars = 50 μm. 
Figure 15. Merged images showing DAPI (blue), CD31 (red) and a-SMA (green) staining of 
tubule formation in response to degree of overlap in PDGF and BMP delivery (CD31 staining 
channel comprises Figure 15.) 
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Figure 16. Tubule quantification (area, length, branches loops) of groups represented in Figure 14 
showing that 4 days of overlap in growth factor delivery results in significantly greater tubule 
formation when compared to all other groups for every measured parameter. Additionally, 2 days 
of overlap in growth factor delivery results in significantly greater tubule area coverage and length 
vs. 8 days and 10 days of overlap. * indicates significant difference from 4 days overlap, # indicates 
significant difference from 2 days overlap when compared using ANOVA followed by post-hoc 
multiple comparisons with Tukey’s test. α = 0.05. 
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4.3.4 Tubule Formation in Response to PDGF Dosage 
A range of soluble PDGF dosages were delivered to co-cultures of HUVECs and hMSCs over the 
course of a 5 day experimental time-frame. PDGF dosages ranged from concentration of 0.1 ng/mL 
to 1000 ng/mL, and were delivered in daily aliquots of 20 μL. In 10 μm slices imaged using a 
Confocal microscope, it was found that tubules appeared to form best under dosages between 1 
ng/mL and 100 ng/mL. Interestingly, both low (0.1 ng/mL) and high (1000 ng/mL) dosages 
resulted in poor tubule formation. 
Figure 17. Tubule formation in response to PDGF dosages ranging from 0.1 ng/mL to 1000 ng/mL 
showing tubule forming in the range of 1 ng/mL to 100 ng/mL. 
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4.3.5 Collagen-1 Expression in Response to Growth Factor Delivery 
Real time qualitative PCR was performed on sequential growth factor delivery groups to assay for 
the presence of early bone formation indicators. (Supplementary Figure 18). Relative mRNA 
expression for collagen-1 was found to be significantly lower in every growth factor delivery group 
as compared to the BMP delivery group (Supplementary Figure 18). Importantly, Matrigel alone 
(without cells or growth factor delivery) was also tested to investigate possible background levels 
of collagen-1 present in the Matrigel matrix. For these samples, no collagen-1 mRNA expression 
was detected, and no amplification was shown over the course of 40 PCR cycles (data not shown.) 
Additionally, alkaline phosphatase expression was assayed, but not detected in any of the 
experimental groups (data not shown.) 
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Figure 18. Relative levels of mRNA expression for collagen-1 using 18S as an endogenous control 
and BMP-2 as the reference sample showing that BMP-2 delivery results in greater collagen one 
expression compared to other growth factors delivery regimens. 
4.4 DISCUSSION 
The objective of this study was to determine how the pattern of presentation of angiogenic and 
osteogenic growth factors affect vascular formation in the context of bone regeneration. While 
some recent bone regeneration studies design controlled release systems for temporal separation 
62 
of growth factors [102, 119, 121], cellular responses to multiple growth factor timing and overlap 
are otherwise largely uncharacterized.  For the purposes of this study, we utilized a 3D Matrigel 
plug model in order to focus on the sequence, timing, and overlap of two growth factors involved 
in bone regeneration that influence both angiogenesis (PDGF) and osteogenesis (BMP-2) in co-
culture with endothelial cells and mesenchymal stem cells. 
The known, potent effect of PDGF on angiogenesis was apparent in our study, which 
suggests that PDGF delivery alone (for the entire course of the study) results in the greatest amount 
of tubule formation (Figure 8). Consistent with this, when delivered in sequence with BMP-2, 
longer PDGF delivery results in greater amount of tubule formation, as expected (Figure 12). 
PDGF is known to modulate angiogenesis both directly (via endothelial cell PDGFβ 
receptors)[169] and indirectly (via stimulation of VEGF production from other cell types)[44], 
mechanisms which have both been observed in vitro[169, 170]. In addition to the role of PDGF in 
supporting angiogenesis, there is also evidence suggesting that PDGF is capable of acting as a 
chemoattractant for vasculature-stabilizing pericytes, or mural cells [43, 59]. Additionally, it has 
been shown that MSCs are capable of differentiating into this pericyte phenotype and supporting 
the maturation of vasculature [164]. In accordance with this information, we observed that when 
delivering a sequence of PDGF to BMP-2, with increasing length of PDGF delivery, a greater 
amount of α-SMA+ cells were present (Figure 11), suggesting that some MSCs present in the cell 
cultures may be acting phenotypically as pericytes, supporting tubule integrity [164]. This is 
significant, given that the colocalization of α-SMA+ cells with CD31+ cells indicates mature 
tubule formation [171]. Importantly, the positive α-SMA staining of hMSCs does not conclusively 
determine their differentiation into perictyes. While positive α-SMA staining coupled with the 
colocalization of hMSCs in proximity to tubules suggests the possibility of hMSCs acting as 
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pericytes, microscopic images depicting the presence of cellular projections wrapping the 
endothelial cells would more definitively indicate a pericyte cellular phenotype [172-174]. By co-
culturing HUVECs and MSCs in this model, we add a layer of complexity over single cell culture, 
including an additional cell type and providing a platform for cellular crosstalk to occur. The 
HUVEC/MSC co-culture may also be useful in exploring cellular tendency towards bone 
formation at later timepoints, as MSCs may serve as osteoblast precursors [175]. 
Due to the stage-wise nature of bone repair, involving early steps of vascular infiltration 
and cell recruitment (coordinated by PDGF), followed by osteoblast proliferation and 
mineralization (upregulated by BMP-2) [58], we hypothesized that PDGF delivery followed by 
BMP-2 delivery would most effectively promote tubule formation. The results illustrated in Figure 
9 demonstrate that the PDGF to BMP sequence did indeed result in greater tubule formation than 
either the reverse sequence (BMP to PDGF) or simultaneous delivery of PDGF and BMP. These 
results agree with existing studies that also suggest the importance of order in growth factor 
delivery for stage-wise regeneration [38, 85, 176]. For example, it has been shown that to promote 
specific, ordered stages of angiogenic repair, certain growth factors must be delivered in a 
particular sequence (not in reverse or simultaneously) for optimal results [38, 85]. Importantly, it 
appears that an antagonistic effect may exist between PDGF and BMP signaling, as the 
simultaneous delivery of these growth factors results in significantly less tubule formation when 
compared to sequential growth factor delivery (Figure 10.) This is not surprising, given evidence 
that a molecular antagonism (regulation of microRNA-24 expression) has been observed between 
PDGF and BMP signaling that controls cellular phenotypes, particularly vascular smooth muscle 
cell phenotypes [153].   Specifically when considering bone repair, these results are consistent 
with a previous study that suggests temporal or spatiotemporal separation of angiogenic and 
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osteogenic growth factors is beneficial for both the vascularization and mineralization stages of 
healing [176].  
While complete overlap in PDGF and BMP-2 delivery resulted in poor tubule formation, 
we observed that some degree of overlap in the transition from PDGF to BMP-2 delivery may be 
beneficial for tubule formation (Figure 12). Greater amounts of tubule formation were observed 
when there was a 2-4 day overlap in growth factor delivery as compared to a “hard transition” in 
growth factor delivery, with no overlap in the sequence of PDGF to BMP-2 (Figure 12).  This 
observation may be explained, in part, by how biological cascades of growth factors are regulated 
and expressed in situ. In the general wound healing model, there is evidence that growth factors 
are expressed in a cascading fashion, with overlapping waves of expression that may coincide for 
a few hours to days [177, 178]. Likewise, it has been shown that phases of bone healing and 
remodeling are not discrete stages, but instead, have some amount of overlap in transition [90, 
179].  In addition to these observations, moderate overlap (2-4 days) in PDGF and BMP-2 delivery 
resulted in greater tubule formation than longer periods of overlap (6-10 days, Figure 12), which 
agrees with literature suggesting that the prolonged expression of PDGF may be deleterious for 
mineralization stages bone formation [65, 180, 181], and therefore, may be most effective when 
restricted to earlier healing stages. 
Importantly, a baseline amount of CD31+ staining was observed in each experimental 
group, including Matrigel constructs with no delivered PDGF or BMP-2. This may be explained 
by the minor amount of growth factors found in Matrigel, including transforming growth factor 
beta (TGF-β) and insulin-like growth factor 1 (IGF-1) [182]. However, these low levels of 
background growth factors are not predominantly responsible for tubule formation, as there were 
statistically significant differences observed across experimental groups based on the presence or 
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absence of PDGF and BMP-2 (Figure 10). Additionally, according to the manufacture’s analysis 
(Corning), concentrations of growth factors in the Matrigel used in these experiments range from 
0.1 pg/mL - 5 ng/mL (one to six orders of magnitude less than the quantities of PDGF and BMP-
2 used). In addition to Matrigel, additional biomaterials were considered as matrices for 
conducting cell-based assays, including collagen-1 and hyaluronic acid. Collagen-1 (Rat tail 
collagen-1, Fisher Scientific) was investigated as a possible alternative three-dimensional matrix 
for tubule formation. However, it was found to considerably shrink in size over the course of the 
ten day study (data not shown), limiting the experimental time-frame, and prohibiting endpoint 
assays for tubule formation. This shrinkage in size of the hydrogel has been observed in other 
studies, and is attributed to the contraction of collagen via cellular activity during successful 
wound healing [183]. In addition to these hindrances, collagen-1 is major component of 
avascular tissues in vivo, such as cartilage, ligament and fascia [184-187], suggesting it may not 
be the optimal material for conducting tubule formation assays. A hyaluronic assay matrix 
(Hystem, Sigma Aldrich) was also investigated for potential use as a template for 3D cell assays. 
During immunofluorescent analysis of tubule formation, it was found that the hyaluronic acid-
based matrix had a tendency to autofluoresce, confounding results (data not shown).  Like 
collagen-1, hyaluronan too, is commonly found in avascular tissues, including cartilage and 
connective tissues [188-190]. Another downfall of  using a single component of ECM, such as 
collagen or hyaluronan is the oversimplification of the complex extracellular matrix [191]. A 
potential method for avoiding this oversimplification is to incorporate several matrix components 
through the use of decellularized matrix as a three-dimensional cell-culturing system. However, 
while decellularized matricies represent native ECM composition and structure, its procurement 
requires biological, chemical, and physical methods of treatment to fully remove cellular 
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material [191]. In comparison to decellularized ECM, Matrigel may more accurately recapitulate 
a native healing environment because of its combination of ECM components and low levels of 
growth factors [161, 192]. Given the challenges and limitations associated with alternative 
matrix materials, Matrigel was chosen as the biomaterial to be used in all in vitro three-
dimensional assays. 
Our current investigation of growth factor presentation on tubule formation suggests that 
PDGF and BMP-2 presentation patterns do indeed play a role in angiogenesis, by affecting the 
quantity and organization of tubules. Due to the flexibility of our model, further studies to explore 
the effects of growth factor timing on a variety of cell types is possible. To assess the impact of 
growth factor delivery schemes on the expression of bone markers and later stages of 
mineralization, future studies will focus on later timepoints (14-28 days) when these effects 
become apparent. Importantly, the evaluation of later time-points may provide additional 
information on how earlier growth factor timing patterns affect downstream healing activity, such 
as the eventual mineralization of bone. Additional cell types and growth factors can also be 
explored, along with in vivo validation, as there are many factors involved in fracture healing aside 
from those explored in this study. While this model provides a controllable in vitro system to 
evaluate cellular responses, the complexity of the system can be increased to better recapitulate an 
in vivo environment. Ultimately, in vivo validation studies must be performed in the future to 
confirm these results. 
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4.5 CONCLUSIONS 
In summary, in this chapter, we have demonstrated the utilization of a three dimensional, in vitro 
model that permits the exploration of the effects of growth factor timing on vascularization in the 
context of bone repair with a large degree of variables. Specifically, with this system, we were 
able to evaluate resulting tubule formation from variations in sequence, length, and degree of 
overlap in growth factor delivery. We observed that the sequence of angiogenic (PDGF) to 
osteogenic (BMP-2) presentation resulted in greater tubule formation that the reverse presentation 
or co-delivery of these growth factors. Additionally, moderate overlap (2-4 days) in the sequence 
of PDGF to BMP-2 delivery resulted in greater tubule formation in comparison to the absence of 
overlap as well as prolonged overlap.  This approach may be further applied to investigate the 
effects of growth factor timing, overlap, and sequence on additional cell types, later time points to 
gather information that may lead to improved in vivo outcomes. The resulting information could 
serve as a valuable contribution to our understanding of the effects of growth factor timing and 
sequence in the bone regeneration niche, and ideally, advance the development of growth factor 
therapies for fracture repair. 
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5.0 FABRICATION OF CONTROLLED GROWTH FACTOR DELIVERY 
SCAFFOLDING 
5.1 INTRODUCTION 
In previous chapters, we have discussed several strategies for improved bone regeneration.  
Currently, the gold standard treatment of fracture non-unions is currently autografting [193]; 
because these grafts are taken from the patient’s own body, it serves as a non-immunogenic, 
osteogenic, osteoconductive, osteoinductive graft, delivering osteoblast precursors and growth 
factors to the site of healing [10, 194]. However, although autografts are an effective, gold-standard 
treatment, there are several drawbacks associated with them, including secondary surgical sites, 
and increased likelihood for blood loss and infection [195, 196]. To overcome these limitations 
while still providing instructive cues from growth factors to jumpstart fracture repair, biomaterials 
(such as collagen sponges) loaded with bone morphogeneic protein 2 (BMP-2) have been approved 
for clinical use in 2004 [197]. Delivering exogeneous BMP-2 stimulates bone healing through the 
proliferation and differentiation of pre-osteoblasts [48], and in the past 12 years of its clinical use, 
has proven very effective. However, due to short half-life of BMP-2 (~6.7 minutes) [197], to 
achieve results, the concentrations of BMP-2 delivered using these methods is approximately 1 
million times physiological concentrations [197], and therefore may lead to complications, such 
as presentation to neighboring tissues and ectopic bone formation [198]. To mitigate these 
complications, a variety of methods for more controllably delivering BMP-2 have been explored, 
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one of which is its encapsulation in polymers [45]. Through these methods, BMP-2 may be 
delivered in lower concentrations to the target tissue over an extended period of time.  
While the extended, controlled delivery of BMP-2 has shown to be effective for stimulating 
the proliferation and differentiation of pre-osteoblasts for the ultimate formation and 
mineralization of bone tissues [31], another critical stage of fracture healing, angiogenesis, may 
also benefit from the programmed release of an angiogenic factor. If an angiogenic growth factor 
could be controllably delivered alongside BMP-2, angiogenesis may increase in synthetic 
scaffolding, and lead to more successful healing outcomes. Because recent evidence is starting to 
show that recreating the biological cues that orchestrate the regenerative process is not as simple 
as delivering two (or more) growth factors simultaneously (Chapter 3), the spatiotemporal 
separation of angiogenic and osteogenic growth factor through controlled release may represent a 
reasonable approach for manipulating growth factor presentation. In support of this idea, the work 
of Chapter 4 demonstrates that the timing, dosage, sequence and overlap of PDGF and BMP-2 
delivery impacts early angiogenic tubule formation. These recent results are fascinating because 
they suggest that the absence of a signal at a given period of time may be equally important to the 
presence of that signal at another time.  To translate these findings into a system capable of further 
testing and potential clinical application, it is essential to engineer a system of autonomously 
delivering the growth factors according to the parameters in Chapter 4. Additionally, to provide a 
substrate for new bone growth, it is important to incorporate these growth factor delivery systems 
within a scaffolding construct. 
To explore the possibility of creating such a scaffold, we employed the use of three 
biomaterials in combination to fabricate a scaffold capable of controllably releasing a desired 
series of growth factors. For the main structure of the scaffold, we used a formulation of calcium 
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phosphate, a biomaterial that is well-recognized for its osteoconductive properties, 
biocompatibility, and chemical similarity to bone composition (among other attributes) [199-201]. 
By combining calcium phosphate cement with PLGA microspheres, we were able to create a three 
dimensional scaffold with an interconnected porous network. Alginate hydrogels and 
microspheres were used to release a schedule of PDGF and BMP-2 delivery, previously found to 
effectively promote the formation of robust, organized, angiogenic tubules in vitro (Chapter 4). In 
addition to characterizing this scaffold and its release properties, further in vitro studies explored 
the capability of this scaffolding system to stimulate cellular infiltration of the scaffold, induce 
tubule formation and organization, and promote osteogenic differentiation. We hypothesize that 
releasing a programmed schedule of PDGF and BMP-2 (rather than an unorganized presentation 
of growth factors) will have the potential to promote both the formation of angiogenic tubules by 
HUVECs and the osteogenic differentiation of hMSCs. Further, the incorporation of this controlled 
release schedule from an osteoconductive calcium phosphate scaffold may encourage cell 
infiltration of the scaffold. This, together with the promotion of angiogenic tubule formation and 
osteogenic differentiation, will aid in the creation of a scaffold capable of orchestrating both the 
angiogenic and osteogenic phases of bone regeneration.  
5.2 MATERIALS AND METHODS 
In the following experiments, we aimed to characterize growth factor release behaviors from 
microsphere and hydrogel formulations and fabricate a porous, three-dimensional hybrid alginate-
calcium phosphate scaffold capable of controllably releasing a schedule of PDGF and BMP-2 
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delivery. Additionally, we aimed to assess cellular responses to growth factor release schedules 
from this hybrid scaffold. 
5.2.1 Scaffold Fabrication 
To fabricate the porous, three-dimensional hybrid alginate-calcium phosphate scaffold, we first 
custom-fabricated spherical poly-lactic-co-glycolic PLGA microspheres as a porogen. Alginate 
microspheres and hydrogels were fabricated to controllably release PDGF and BMP-2. These 
components were then incorporated into the porous calcium phosphate scaffolding as follows: 
5.2.1.1 PLGA Particle Fabrication for Scaffold Porogen 
Blank PLGA microspheres (not containing any growth factor) were fabricated using a double 
emulsion evaporation procedure. 200 mg of PLGA polymer (poly(D,L-lactide-co-glycolide), 24-
36 kD, 50:50 lactide:glycolide, ester terminated, Sigma-Aldrich) was dissolved in 4 mL 
dichloromethane (Sigma-Aldrich). Dissolved PLGA was then sonicated with 200 μL of deionized 
water, then pipetted dropwise through a 250 μm sieve into a solution of 1% polyvinyl alcohol in 
deionized water (Polysciences, Inc.) spinning at 400 rpm. Following dichloromethane evaporation 
(3 hrs), microspheres were collected via centrifugation, washed four times with deionized water, 
frozen, and lyophilized.  
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5.2.1.2 Hydrogel Fabrication for PDGF Release 
Alginate hydrogels were fabricated by mixing 30 mg of medium viscosity sodium alginate (MP 
Biomedicals, LLC) into 3 mL of deionized water until alginate was fully dissolved to constitute a 
1% solution.  A 30 μL aliquot 200 μg/mL of soluble PDGF-BB (Thermo Fisher) was then gently, 
homogeneously stirred into each 200 μL of alginate solution. Once the aliquot of growth factor 
was homogenously mixed into the alginate solution, the hydrogel was chemically crosslinked with 
1 mL of 700 mM calcium chloride (Fisher Scientific) for 10 minutes. Following crosslinking, the 
hydrogels were washed with deionized water to remove excess crosslinking solution. 
To produce a hydrogel with a reasonably consistent thickness and shape, 200 μL aliquots 
of 1% alginate + PDGF were transferred to a flat-bottom 96-well plate (Corning). A rounded disk 
of medium porosity, medium flow rate filter paper (Fisher Scientific) was place atop the alginate 
hydrogel, and 700 mM calcium chloride crosslinker was added dropwise on top of the filter paper 
to allow slow, even crosslinking of the hydrogel. Several other methods of creating hydrogels of 
consistent thickness were explored (Figure 27), however, the above described method was found 
to produce hydrogels most consistently. 
Release behavior was assayed for three different conditions: from a 1% alginate hydrogel, 
from a 1% alginate hydrogel applied as a coating the ReCaPP scaffold. 
5.2.1.3 Microsphere Fabrication for BMP-2 Release 
Single emulsion alginate microspheres were fabricated by mixing 300 mg of sodium alginate in 
10 mL of deionized water until alginate was fully dissolved to constitute a 3% alginate solution. 
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A 200 μL aliquot of 100 μg/mL soluble BMP-2 (Shenandoah) in deionized water was 
homogeneously mixed into the alginate solution. The BMP-2 -alginate solution was then placed 
into 5 mL syringes and left undisturbed for 30 minutes to remove air bubbles from the solution. 
Once bubbles were removed from the alginate solution, alginate was added dropwise into 2.5% 
solution of Span 80 in iso-octane and homogenized at 5000 RPM. Next, 3 mL of 30% Tween 80 
in iso-octane was added and homogenized at 5400 RPM. 700mM calcium chloride solution was 
then used to crosslink the particles, which were further cured with 2-propanol. Following 
fabrication, the particles were collected via centrifugation, washed twice with 2-propanol, then 
washed 3 times with deionized water. Collected particles were then frozen and lyophilized.  
5.2.1.4 Preparation of Cement Powders and Liquid 
To produce ReCaPP cement powder, alpha-tri-calcium phosphate (α-TCP, pure phase, Sigma-
Aldrich), calcium carbonate (99%+, Acros Organics), calcium sulfate di-hydrate (99%+, Acros 
Organics) and disodium hydrogen phosphate (99%+, Sigma-Aldrich) were mixed in an agate 
mortal-pestle for 30 minutes and stored in 50 mL Falcon Tubes for use. The composition of the 
cement powder consisted of ratios of 72.7% α-TCP, 9.1% calcium carbonate, 9.1% calcium sulfate 
di-hydrate, and 9.1% disodium hydrogen phosphate, by weight.
The liquid component of the cement (nano-CaPs) is a colloidal solution of nano-sized 
calcium phosphate homogeneously dispersed in a buffer solution. On a per-millileter basis, this 
solution is created by adding 500 μL of 0.75 M CaCl2 dropwise into 500 μL of phosphate 
precursor solution. Phosphate precursor solution consisted of 0.357 M NaCl (99.5%+, Fisher 
Scientific), 13 mM KCl (99%+, Fisher Scientifict), 15 mM dextrose monohydrate (Fisher 
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Scientific), 64 mM HEPES free acid (99.5%+, Sigma-Aldrich), and 1.91 mM Na3PO4.12H2O 
(98%+, Acros Organics). 
5.2.1.5 Hybrid Scaffold Fabrication 
To fabricate hybrid, three-dimensional scaffolding consisting of calcium phosphate cement, BMP-
2-releasing microspheres, and PDGF-BB-releasing hydrogel, first a porous cement scaffold was
created by mixing 100 μm PLGA microspheres with ReCaPP cement powder in a ratio of 20 mg 
microspheres to 30 mg ReCaPP. When used in cell-culturing assays, the cement ReCaPP powder 
and microsphere mixture was sterilized via UV light for 30 minutes. To form scaffolds 33 uL of 
liquid nano-CaPs was mixed into the ReCaPP-microsphere powder. This slurry was then 
compressed in a cylindrical mold to create disks. After initial setting, the resulting tablet was dried 
at 37ᴼC overnight. The 50 mg tablet scaffolds were then placed in three successive washes of 
dichloromethane for 10 minutes each to completely dissolve PLGA microspheres from the 
scaffold. After the last wash of dichloromethane evaporated, scaffolds were then rinsed in 
deionized water three times to remove residual dichloromethane and dried at room temperature. 
To infiltrate the ReCaPP cement scaffold with BMP-2-alginate microspheres, scaffolds 
were placed in a glass Pyrex dish with a solution of 10 mg of BMP-2-alginate microspheres in 500 
μL deionized water. Pyrex dishes were then placed in the water bath of a Bronson 1510 sonication 
bath, and sonicated at full power for 30 minutes. Following BMP-2-alginate microsphere 
infiltration, scaffolds were frozen and lyophilized for 24 hours.  
A PDGF-BB-releasing hydrogel was applied to the scaffolds as an outer coating by submerging 
scaffolds for 10 minutes in a 1% alginate solution, which was fabricated as described previously 
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in “Hydrogel Fabrication for PDGF-BB Release.” For scaffolds used in cell culture, 10 μL of 200 
μg/mL PDGF-BB was mixed into each 100 μL solution of alginate coating. Alginate solutions and 
calcium chloride crosslinking solutions were both UV sterilized prior to cell culture use. Once 
PDGF-BB alginate coatings were applied to porous ReCaPP scaffolds, they were crosslinked by 
submerging the scaffolds in a 700 mM calcium chloride solution for an additional 10 minutes. 
Completed, crosslinked scaffolds were rinsed in deionized water to remove residual calcium 
chloride solution. 
5.2.2 Scaffold Degradation Analysis 
To determine degradation rates of the scaffold, particularly the growth factor-containing alginate 
components, scaffolds were fabricated by mixing 40 mg alginate microspheres with 60 mg 
ReCaPP cement powder. For purposes of the degradation study, BMP-2 was not encapsulated in 
the alginate microspheres. The ReCaPP/alginate microsphere mixture was then mixed with 150 
μL of liquid nano-CaPs, compressed in a cylindrical mold, and allowed to dry overnight at 37ᴼC. 
The following day, a 1% alginate hydrogel was applied as a coating to the scaffolds, as described 
in “Hybrid Scaffold Fabrication.” Scaffolds were placed in 1.5 mL lo-bind Eppendorf tubes with 
1 mL phosphate buffered saline (PBS) and subject to end-over-end rotation at 37ᴼC. PBS solution 
was removed daily and replaced with fresh PBS. Scaffolds were removed from solution at 
experimental timepoints (days 1-10, 15, 20, 40) and frozen in liquid nitrogen, and lyophilized for 
dry weight measurement. 
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5.2.3 Controlled Growth Factor Release Assay 
To determine the release rate of BMP-2 from alginate microspheres, 10 mg of alginate 
microspheres were suspended in 1 mL of PBS in a lo-bind Eppendorf tube and subject to end-
over-end rotation at 37ᴼC. At predetermined experimental time-points, particle suspensions were 
centrifuged at 1000 RPM and supernatant was collected and frozen at -20ᴼC. Fresh PBS was added, 
particles were re-suspended, and again end-over-end rotated at 37ᴼC. At the conclusion of the 
study, all frozen supernatant samples were thawed and assayed for BMP-2 concentration using a 
human BMP-2 ELISA assay (R&D Systems).  
To determine the release rate of PDGF-BB from alginate hydrogels, 200 μL hydrogel 
samples were submerged in 1 mL of PBS release solution in a lo-bind Eppendorf tube and subject 
to end-over-end rotation at 37ᴼC. PBS release solution consisted of PBS supplemented with SDS 
(50mM) and 0.1% BSA to further prevent released PDGF-BB from sticking to the Eppendorf tube. 
At predetermined experimental time-points, hydrogel samples were either removed and/or 
centrifuged to separate the samples from the PBS solution supernatant. Collected supernatant 
samples were frozen at -20ᴼC until the conclusion of the experiment, whereupon they were thawed 
and analyzed for PDGF-BB content using a PDGF-BB ELISA assay (R&D Systems). 
5.2.4 Tubule Formation in Repsonse to Controlled Release Growth Factor Delivery 
Well inserts of 8 μm, 24-well transwell plates (Sigma-Aldrich) were filled with 250 μL of growth 
factor reduced, phenol-free Matrigel (LDEV free, Fisher Scientific).  Human umbilical vascular 
endothelial cells (HUVECs, Lonza) and human bone marrow-derived mesenchymal stem cells 
(BM hMSCs, Life Technologies) were seeded at a density of 1.5 x 105 cells per well, in a 1:1 
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(hMSC : HUVEC) ratio.  The lower reservoirs of MSC-HUVEC co-cultures we filled with 500 μL 
of a 1:1 ratio of endothelial basal media (Lonza) and minimum essential media (Life Technologies) 
supplemented with 1% penicillin-streptomycin (Life Technologies) and 1% antibiotic-antimycotic 
(Life Technologies) to provide hydration to Matrigel plugs. 
For positive control experimental groups, soluble growth factors were delivered by daily 
hand-dosing of PDGF-BB and BMP-2 concentrations to closely match growth factor release 
profiles of PDGF-BB and BMP-2 delivered by controlled release mechanisms. For controlled 
release experimental groups, 100 μL alginate hydrogels were embedded within the Matrigel to 
release PDGF-BB.  
At the conclusion of the experimental timeframe (7 days), Matrigel plugs were removed 
from transwell inserts, embedded in TissueTek (Fisher Scientific) and snap frozen in liquid 
nitrogen.  Frozen sections (10 μm) were incubated with primary antibody mouse anti-human 
CD31/PECAM-1 (R&D Systems) and secondary antibody donkey anti-mouse IgG (R&D 
Systems) to identify endothelial cell activity and vessel formation.  Images of CD31-stained 
sections were taken at 20X and 10X using a Nikon inverted light microscope, then analyzed using 
WimTube software (Wimasis Image Analysis, GmbH). Images at a magnification of 10X were 
used for analysis to gain a larger representative sample area.  WIMASIS software was used for 
analysis of four parameters for every image: total area covered by vessels, total length of vessels, 
number of branching points, and number of closed loops. 
To identify MSC differentiation towards a pericyte phenotype when exploring length of 
PDGF delivery, slides were incubated with primary antibody rabbit anti-alpha smooth muscle actin 
(ab5694, Abcam) and secondary antibody goat anti-rabbit IgG H&L (Alexa Fluor 488, Abcam). 
Images of slides were taken at 20X using a Nikon inverted light microscope. 
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5.2.5 Cellular Infiltration of the Scaffold in Response to Growth Factor Delivery 
Alginate hydrogels were prepared as described in Materials and Methods Section 5.1.1.4. Four 
growth factor delivery groups were explored: hydrogels releasing no growth factor (No GF), 
hydrogels releasing PDGF alone (PDGF), hydrogels releasing BMP-2 alone (BMP-2), and 
hydrogels releasing both PDGF and BMP-2 at the same time (PDGF+BMP) Hydrogels were 
placed in transwell inserts of an 8 μm 24-well transwell plate (Sigma Aldrich). Atop each hydrogel, 
porous ReCaPP scaffolds were placed into each transwell insert, and snugly fit to prevent liquid 
leakage between the scaffold and transwell insert wall. Prior to fitting ReCaPP scaffolds in 
transwell inserts, scaffolds were soaked in a solution of 1% BSA in PBS to encourage cell 
attachment to scaffold surfaces. A co-culture of HUVECs and hMSCs were then seeded atop 
porous ReCaPP scaffolds. Lower transwell reservoirs were filled with 500 μL of media () to 
provide hydration to the alginate hydrogels. At the end of the experimental time-frame (7 days) 
scaffolds were removed from transwell inserts, snap-frozen in liquid nitrogen and lyophilized. 
Subsequently, scaffolds were broken in half to image vertical cross-sections. Scaffolds were 
sputter coated and imaged with a Scanning Electron Microscope. 
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Figure 19. Schematic of transwell set up used to assay cell infiltration in response to growth factor 
releasing alginate hydrogels. 
5.2.6 Alkaline Phosphatase Expression in Response to Growth Factor Delivery 
Lower surfaces of a 8 μm 24-well transwell plate (Sigma Aldrich) were seeded with bone marrow-
derived human mesenchymal stem cells (BM hMSCs, Life Technologies) at a density of 1x104 
cells per well. Each well was filled with 1 mL of α-MEM media (Life Technologies) supplemented 
with 1% penicillin-streptomycin (Life Technologies) 1% antibiotic-antimycotic (Life 
Technologies) and 10% fetal bovine serum (Fisher Scientific) which was changed every 2-3 days 
throughout the experiment. Transwell inserts contained the following experimental scaffold 
groups: ReCaPP scaffold with no additional growth factor (No GF), ReCaPP scaffold with PDGF-
BB-eluting alginate hydrogel (PDGF), ReCaPP scaffold with BMP-2-eluting alginate 
microspheres (BMP), and ReCaPP scaffold with PDGF-BB-eluting alginate hydrogel and BMP-
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2-eluting alginate microspheres (PDGF to BMP). After scaffolds we placed in transwell inserts,
100 μL of media was added to hydrate the scaffold and facilitate release of growth factors from 
hydrogels and miscropheres. 
At each experimental time-point (7 days, 14 days, 21 days, 28 days) transwell inserts were 
removed, media was aspirated, and cells were assayed for alkaline phosphatase (ALP) expression 
using an AP Staining Kit (System Biosciences). Following staining, wells were imaged using a 
Nikon Inverted Light Microscope at 20X magnification. 
Figure 20. Schematic of transwell set-up used to assay alkaline phosphatase expression in 
response to PDGF eluting alginates hydrogels and BMP-2 eluting alginate microspheres. 
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5.3 RESULTS 
Several biomaterials (calcium phosphate, alginate, and PLGA) and processing methods were 
used to fabricate a three-dimensional porous scaffold capable of controllably releasing a 
predetermined schedule of PDGF and BMP-2 release. We observed that a  co-culture of 
HUVECs and hMSCs infiltrated the calcium phosphate scaffold in repsonse to a PDGF gradiant 
presented from an alginate hydrogel coating. Additionally, controlled PDGF release promoted 
similar angiogenic tubule formation in comparison to hand-delivered PDGF schedules. Scaffolds 
controllably releasing PDGF and BMP-2 stimulated the production of alkaline phosphatase, 
indicated the tendency of hMSCs towards an osteoblastic phenotype. 
5.3.1 Hybrid Scaffold Fabrication 
PLGA microspheres were fabricated to be morphologically spherical, with a smooth surface and 
average size of 90-100 μm in diameter (Figure 21). Miscrospheres were mixed with ReCaPP 
powders and liquids, compressed, and hardened overnight, resulting in a tablet-shaped ReCaPP 
scaffold with embedded PLGA microspheres (Figure 22).  By mixing these miscropheres with 
ReCaPP cement powders in a ratio of 40 mg microsphere to 60 mg ReCaPP powder by weight, 
and subsequently dissolving PLGA microspheres with dichoromethane, porous ReCaPP scaffold 
were fabricated (Figure 23). To fabricate tablet scaffolds of various thicknesses, increasing 
amounts of PLGA microspheres and ReCaPP powder were mixed, from a total weight of 25 mg 
of 100 mg, while maintaining the same 2:3 weight ratio of microspheres to ReCaPP powder. As 
shown in Figure 24, by increasing amounts of microspheres and ReCapp powder, tablet scaffolds 
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varied in thickness from approximately 900 μm (25 mg total) to approximately 2.5 mm (100 mg). 
For all cellular experiments, 25 mg tablets were used. 
Using 25 mg total weight scaffolds (10 mg PLGA microspheres + 15 mg ReCaPP powder), 
PLGA microspheres were dissolved from the scaffolds, and subsequently, the scaffolds were 
reinfiltrated with 10 mg of ~20 μm alginate microspheres (Figure 25) via sonication. Resulting 
scaffolds (Figure 25) show that alginate microspheres fully infiltrated porous ReCaPP scaffolding, 
filling pores in the center of the cross-sectioned scaffold. 
Figure 21. 100 μm PLGA microspheres used as a porogen in ReCaPP scaffolds. 
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Figure 22. A ReCaPP/PLGA microsphere scaffold edge prior to PLGA microsphere dissolution 
showing distribution and density of PLGA microspheres embedded throughout the scaffold. 
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Figure 23. SEM showing porosity of ReCaPP scaffold after PLGA microspheres have been 
dissolved. 
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Figure 24. Tablet-shaped ReCaPP-PLGA microsphere scaffolds of various thickness, showing 
thickness increase with increasing amounts of PLGA microspheres and ReCaPP powders used to 
fabricate scaffolding. 
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Figure 25. SEM of porous ReCaPP scaffold that has been reinfiltrated with BMP-2-alginate 
microspheres, showing that the BMP-2-alginate microspheres penetrate to the center of the 
scaffold. 
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Figure 26. SEM of alginate microspheres showing that fabricating microspheres at speeds of 5400 
RPM results in spheres approximately 20 μm in diameter that can be used to reinfiltrate the 100 
μm pores of porous ReCaPP scaffolding. 
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Figure 27. Different methods of adding calcium chloride crosslinker to alginate hydrogels, 
showing that hydrogels with the most consistent shape and thickness are generated through the 
addition of crosslinker through filter paper. 
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Figure 28. SEMs of porous ReCaPP scaffolds representing several methods of re-infiltrating the 
scaffolds with 20 μm alginate microspheres. Alginate microspheres are highlighted inside red 
circles. Of the four methods shown, sonicating the scaffold with a solution of microspheres 
suspended in diH2o most effectively distributed microspheres throughout the scaffold. 
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5.3.2 Scaffold Degradation 
Degradation of scaffolds was measured over 40 days. Dry weights of three scaffolds comprised of 
ReCaPP cement, 3% alginate microspheres, and 1% alginate hydrogels were measured for each 
time-point. Degradation, measured by mass loss, occurred primarily over the first 20 days of the 
assay timeframe, with no additional significant mass loss measured at day 40.  
Figure 29. SEMs showing scaffolds prepared for the degradation study, showing 3% alginate 
microspheres embedded in a ReCaPP matrix with a 1% alginate hydrogel coating. 
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Figure 30. A graphical representation of the degradation of the alginate ReCaPP scaffold over 40 
days, showing an approximate mass loss of 40 mg dry weight. 
5.3.3 PDGF and BMP-2 Release Profiles 
Three formulations of alginate hydrogels were assayed for PDGF release: a 1% hydrogel, a 1% 
hydrogel applied as a coating to ReCaPP scaffolding, and a 3% hydrogel applied to ReCaPP 
scaffolding (Figure 31). Over the first six days of release, the 1% alginate hydrogel exhibited fast 
burst release of PDGF, which was complete by day four. Both 1% and 3% hydrogels, when applied 
as a coating to scaffolds exhibited more steady, linear release of PDGF, with PDGF releasing more 
slowly from 3% alginate hydrogel coatings. 
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Release profiles of the PDGF from 1% alginate hydrogel coatings and BMP-2 from 3% alginate 
microspheres show early PDGF release, and later, delayed BMP-2 release (Figure 32). BMP-2 
release begins on day 5, overlapping with PDGF release for 3 days (day 5-day 7). 
Figure 31. Release of PDGF from alginate hydrogel formulation showing burst release of PDGF 
from the 1% hydrogel. When hydrogels are applied as a coating to ReCaPP scaffolds, release 
profiles become relatively linear over the first 6 days of release, indicated a more steady release of 
PDGF. 
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Figure 32. Release profiles of PDGF from 1% alginate hydrogels applied as a coating to ReCaPP 
scaffold, and BMP-2 from 3% alginate microspheres. PDGF release occurs over the first 7 days, 
while BMP-2 release subsequently begins on day 5, overlapping for three days with PDGF release. 
5.3.4 Tubule Formation in Response to Controlled Release Growth Factor Delivery 
PDGF was delivered to a co-culture of hMSCs and HUVECs in a Matrigel plug over the course of 
7 days. Two methods of delivery were used: controlled delivery of PDGF from an alginate 
hydrogel and daily hand-dosing of PDGF via pipetting soluble aliquots into the Matrigel plug. As 
seen in Figure 34, both methods of PDGF delivery resulted in similar density and organization of 
tubules. 
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Figure 33. Wimasis software overlay of tubule formation in response to PDGF dosing techniques 
showing comparable tubule formation in response to controlled release PDGF delivery with tubule 
formation in response to daily hand-dosed cell cultures. 
Figure 34. Results of unpaired students t-test with Welch’s correction showing that there is no 
statistical significant difference in tubule area coverage or tubule length for daily dosing vs. 
controlled delivery PDGF. 
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5.3.5 Cellular Infiltration of Scaffold in Response to Growth Factor Delivery 
To evaluate the efficacy of PDGF to recruit cells to the scaffold, PDGF hydrogels were applied to 
one side of the scaffolding (creating a gradient of growth factor release across the scaffolding), 
while a co-culture of HUVECs and hMSCs were seeded on the opposite side of the scaffolding. 
At the experimental endpoint, scaffolds were broken in half to reveal a vertical cross-section and 
imaged with a scanning electron microscope to identify cellular locations within the scaffolding 
(Figure 35). In response to PDGF release, cellular infiltration was observed through approximately 
75% of the 900 μm thick, 3D scaffold over the course of 7 days (Figure 36). In comparison, when 
no growth factor was released from the hydrogel coatings, cell infiltration was only observed to 
penetrate approximately 25% of the way into the scaffold. Interestingly, when BMP-2 was released 
from the hydrogel coating, no cells were observed to infiltrate the scaffold. When PDGF and BMP-
2 were delivered simultaneously from the hydrogel, cells penetrated through approximately 30% 
of thickness of the scaffold. 
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Figure 35. SEM of a cross-section of porous ReCaPP scaffolding indicating depth of cell 
infiltration. Blue dotted lines demarcate upper and lower boundaries of the cross-sectional slice; 
the letter “T” identifies the top surface of the scaffold where cells were seeded. Red lines and 
arrows indicate the furthest depth at which cells were found to penetrate the scaffold. Scaffolding 
within the white box is enlarged in the right-hand image to show an example of cells inside of 
scaffold pores. 
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Figure 36. SEMs of porous ReCaPP scaffold cross-sections indicating penetration depth of 
infiltrating cells in response to growth factor gradients. Blue dotted lines demarcate upper and 
lower boundaries of the cross-sectional slice; the letter “T” identifies the top surface of the scaffold 
where cells were seeded. Red lines and arrows indicate the furthest depth at which cells were found 
to penetrate the scaffold. 
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5.3.6 Alkaline Phosphatase Expression in Response to Controlled Growth Factor Delivery 
Programmed PDGF and BMP-2 delivery were presented to hMSC cultures as depicted in Figure 
20. Cell cultures were assayed for ALP expression at three time-points: 7 days, 14 days, and 21
days. At the week 1 time-point (7 days) hMSC cultures with PDGF delivery and no growth factor 
delivery were absent of ALP staining. hMSC cultures with BMP-2 microspheres, as well as 
cultures receiving programmed PDGF to BMP-2 delivery stained positively for ALP expression. 
At day 14, cell cultures receiving BMP-2 and PDGF to BMP-2 treatments showing increased ALP 
staining (over staining amount at 7 days). Continuing with this trend, at day 21, cell cultures subject 
to BMP-2 release and PDGF to BMP-2 release again showed an increase in ALP staining 
compared to previous time-points. Interestingly, cell cultures receiving no growth factor treatment, 
as well as cultures exposed to PDGF release showed trace amounts of ALP staining at day 14, and 
increased ALP expression at 21 days (compared to the same treatment groups at earlier 
timepoints). Importantly, ALP staining in “No GF” and “PDGF” groups showed significantly less 
ALP staining than “BMP-2” and “PDGF to BMP” groups, when compared at the same time-point. 
In Figure 37, ALP expression was assayed for at day 21 under three conditions: cells 
exposed to BMP-2 releasing ReCaPP scaffolding, cells exposed to ReCaPP scaffolding with no 
growth factor, and cells cultured in the absence of ReCaPP scaffolding and growth factors. Cells 
showed no positive ALP staining in the absence of ReCaPP scaffolding and growth factors, a 
moderate amount of ALP expression when cultured in the presence of ReCaPP scaffolding without 
growth factors, and the most ALP staining when subject to ReCaPP scaffolding releasing BMP-2 
(Figure 38). 
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Figure 37. ALP expression (blue staining) at day 7, day 14, and day 21 showing that hMSCs with 
scaffolds releasing only BMP-2, as well as scaffolds releasing a schedule of PDGF to BMP-2 
stimulate ALP expression. hMSCs receiving no growth factor or PDGF show less ALP expression 
at days 7, 14 and 21 versus groups receiving BMP-2 or PDGF to BMP-2. 
Figure 38. ALP expression at day 21 for cells cultured with no additional growth factor and no 
calcium phosphate scaffolding, cells cultured with calcium phosphate scaffolding releasing no 
growth factor, and cells cultured with calcium phosphate scaffolding releasing BMP-2. Scaffolds 
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releasing BMP-2 result in the most ALP staining, while scaffolds releasing no growth factor result 
in a moderate amount of ALP staining. Cells cultured in the absence of calcium phosphate 
scaffolding show no ALP staining. 
5.4 DISCUSSION 
Calcium phosphate cements have been widely investigated for use as synthetic bone scaffolding 
material due to their similarities in composition to bone mineral, biocompatibility, and tunable 
degradation/resorption rates [202-205]. Bioactive components, such as antibiotics and growth 
factors can also be released from calcium phosphate scaffolding, either by adsorbing the proteins 
or antibiotics to the surface of the scaffolding, or through the inclusion of a second biomaterial 
phase, such as synthetic or natural polymers to encapsulate bioactive agents [202, 206]. For 
example, by incorporated vancomycin-loaded PLGA microspheres into calcium phosphate 
scaffolding, it was shown that vancomycin could be released over the course of 100+ days from 
the scaffold [206]. Calcium phosphate cements can also be engineered to be highly porous through 
fabrications methods (such as sintering or salt leaching [207]) or by including degrading polymers 
[206], to form interconnected micro- and macro-porous networks. In this study, we aimed to 
combine these benefits of calcium phosphate scaffolding with a controlled release schedule of 
PDGF and BMP-2. 
While calcium phosphate cements have been used in previous studies to deliver growth 
factors [202], metrics used for evaluating efficacy often focus primarily on mineralization, and 
largely overlook the capacity of a combination of growth factors to generate angiogenic formation. 
For the purposes of this study, we engineered a controlled delivery system capable releasing a 
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schedule of PDGF and BMP-2 that has shown to be effective in generating a robust, organized 
network of angiogenic tubules (Chapter 4). We have incorporated this controlled delivery system 
with a calcium phosphate matrix, and characterized the degradation, release profiles, and cellular 
responses to the resulting hybrid scaffold. 
To fabricate a calcium phosphate scaffolding template with interconnected pores, we 
combined ReCaPP cement with PLGA microspheres at a 2:3 weight ratio of 100 μm microspheres 
to ReCaPP cement (by weight, 40 g microspheres to 60 g ReCaPP cement). In our previous studies, 
similar calcium phosphate constructs were fabricated with a lower ratio of PLGA microspheres 
(37.9 g microspheres to 62.1 g ReCaPP cement), and when evaluated with mercury porosimitery 
intrusion, were found to have a porosity of 73.7% when PLGA microspheres were fully dissolved 
from the scaffold [206]. To ensure at minimum this level of porosity for scaffolding used in this 
study, we increased the ratio of microspheres (of the same diameter) relative to the amount of 
ReCaPP cement. To create scaffolding with immediate porosity (versus porosity that is created 
over time via polymer degradation), PLGA microspheres were dissolved away with 
dichloromethane. For this reason, growth factors were incorporated into the scaffold following the 
creation of a porous network, in part to avoid possible denaturation in the presence of a harsh 
solvent. For the in vitro experiments conducted in this study, several scaffolding total weights were 
explored; ultimately, 25 mg tablets were used to generate scaffolds with an approximate thickness 
of 900 μm.  
Medium viscosity sodium alginate, crosslinked with calcium chloride served as the base 
for both PDGF and BMP-2 controlled release systems. Alginate was chosen as the polymer for 
PDGF release, as other polymers, such as PLGA have been shown to have a “sticky” effect with 
PDGF due to their opposing electronegative (PLGA) and electropositive (PDGF) charges, leading 
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to unpredictable and hindered PDGF release [208]. Additionally, because PDGF is a heparin 
binding protein, it may reversibly bind to alginate hydrogels, enabling its sustained release, a 
phenomenon that has been demonstrated in studies investigating the release of other heparin 
binding growth factors (including VEGF and FGF) from alginate hydrogels [209-211]. Alginate 
hydrogels of 1% and 3% were investigated for PDGF release. When released from a 1% bulk 
hydrogel, PDGF exhibited burst release in the first 48 hours of the release assay. When the same 
1% alginate hydrogel formulation was applied as a coating to ReCaPP scaffolding, linear release 
over 6 days was observed. This difference in release may be attributed to the fact that when the 
alginate hydrogel was applied as a coating, the same aliquot was spread more thinly over the 
scaffold, exposing more of its surface area to be more strongly, consistently crosslinked. This 
hypothesis agrees with known release behaviors of alginate hydrogels in the literature; a greater 
amount of crosslinking will slow protein release from the hydrogel [210, 212]. Similarly, when a 
3% alginate hydrogel was applied as a coating to ReCaPP scaffolding, linear release was observed 
over the first 6 days, at a slower rate of release compared to 1% alginate hydrogels. This difference 
can be explained by the concentration of alginate used in the hydrogels; as the percentage of 
alginate increases, total release is slowed [212]. In addition to generating the desired PDGF release 
profile, alginate hydrogel were chosen for this application because of their ability to be applied as 
a coating. Segregating PDGF to the outside of the ReCaPP prevents potential adsorption (and 
potentially inactivation) of PDGF to the ReCaPP scaffolding, as it might be if it was embedding 
within the scaffold. 
To generate delayed release of BMP-2, the protein was encapsulated in 3% alginate 
microspheres. Not only were we able to achieve delayed BMP-2 release that began on day 7 with 
BMP-2 alginate microspheres, but because they were fabricated at an average size of 20 μm, the 
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microspheres could be reinfiltrated throughout the porous ReCaPP scaffolding, creating local 
BMP-2 release throughout the scaffold, that will be presented to cells that have already infiltrated 
the scaffold in response to earlier PDGF release.  
To evaluate the efficacy of PDGF to recruit cells to the scaffold, PDGF hydrogels were 
applied to one side of the scaffolding (creating a gradient of growth factor release across the 
scaffolding), while a co-culture of HUVECs and hMSCs were seeded on the opposite side of the 
scaffolding. In response to PDGF release, cellular infiltration was observed through approximately 
75% of the 900 μm thick, 3D scaffold over the course of 7 days. In comparison, when no growth 
factor was released from the hydrogel coatings, cell infiltration was only observed to penetrate 
approximately 25% of the way into the scaffold. Interestingly, when BMP-2 was released from the 
hydrogel coating, no cells were observed to infiltrate the scaffold. When PDGF and BMP-2 were 
delivered simultaneously from the hydrogel, cells penetrated through only approximately 30% of 
thickness of the scaffold. It is possible that BMP-2 with PDGF may send conflicting signals to the 
cells and potentially inhibit their migration into the scaffold, giving further support the idea that 
early PDGF release following by later BMP-2 release is beneficial for the ordered regenerative 
stages of bone formation. This hypothesis is in line with evidence that while BMP-2 is a potent 
inducer of MSC differentiation to an osteoblastic phenotype, its activity blocked in situ by BMP-
4 and noggin expression during times when osteoblast recruitment to the fracture site is most active 
[213]. 
To assaying for early tendency of hMSCs towards an osteogenic phenotype, fully 
assembled scaffolds of porous ReCaPP cement with PDGF-releasing alginate hydrogels and 
BMP-2-releasing alginate microspheres were assessed using a transwell system (Figure 20). At 
the day 7 time-point, groups delivering BMP-2 alone and a schedule of PDGF to BMP-2 both 
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stained positively for ALP expression. Groups delivering PDGF alone or no growth factor 
showed no ALP staining at day 7. At day 14, greater amounts of ALP staining were observed in 
cell cultures received BMP-2 and PDGF to BMP-2 growth factors. Cell cultures with no released 
growth factors, and those receiving only PDGF showed relatively small amounts of positive ALP 
staining (when compared with “BMP-2” and “PDGF to BMP” groups) on day 14 and day 21, 
which may be attributed to the osteoconductive (and potentially osteoinductive) effects of the 
calcium phosphate scaffolding [201, 214]. In support of this hypothesis, when cells were cultured 
in the absence of ReCaPP scaffolding and growth factors, no ALP expression was detected at 
day 21 (where as cells cultured in the presence of ReCaPP scaffolding with no releasing growth 
factors showed a moderate amount of ALP staining.) Importantly, these results indicate that 
while PDGF does not induce the expression of ALP (or the differentiation of hMSCs towards an 
osteoblastic phenotype), its early presentation does not inhibit the ability of later BMP-2 
presentation to promote osteoblastic differentiation. These results are supported by evidence that 
PDGF is involved not only during the angiogenic phase of bone repair, but also plays an 
important role in stimulating the cellular events preceding osteogenesis, such as recruiting MSCs 
and stabilizing the blood vessels which guide the orientation of osteoblast sheets [87]. Additional 
staining techniques to assay for mineralization (such as Alizarin Red or Von Kossa staining) 
were not used in these experiments due to the false positive results that would be generated by 
the calcium phosphate scaffolding. As an alternative, to confirm the results indicated by ALP 
staining, osteocalcin staining could be performed on cells seeded in the same transwell 
configuration, as illustrated in Figure 20. Osteocalcin, a protein found in bone tissues is produced 
specifically by osteoblasts [215], and can be assayed for near day 14 of culture [216]. However, 
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osteocalcin is viewed as an indicator of bone turnover (not necessarily bone formation) as it is 
produced and incorporated into the matrix during bone resorption [217]. 
5.5 CONCLUSIONS 
The present study demonstrates the use of degradable PLGA microspheres along with calcium 
phosphate cements to form scaffolds with interconnecting porous networks following the 
dissolution of PLGA microspheres with DCM. Further, these scaffolds can be reinfiltrated with 
smaller, BMP-2-releasing alginate microspheres and coated with PDGF-releasing alginate 
hydrogels to deliver a programmed schedule of these growth factors to cell cultures. The chosen 
delivery schedule of PDGF and BMP-2 has shown to be effective in stimulating cell infiltration of 
the scaffold, generating angiogenic tubule network formation, and promoting alkaline phosphatase 
expression, indicating the potential for this hybrid scaffold system to supply the cues to orchestrate 
vascularized bone regeneration. With further in vivo studies of these materials, the translation of 
this technology from a proof-of-concept model to the development of a new approach for fracture 
healing may be realized. 
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6.0 ORDERED COLLOIDAL CRYSTAL SCAFFOLDING 
The work in this chapter began in collaboration with Melissa Lash, PhD. Materials and Methods 
for crystalline templates and cement-based inverted colloidal crystals were developed in this 
collaboration and adapted from her thesis. 
6.1 INTRODUCTION 
The use of porous scaffolding for bone regeneration provides a template for cellular infiltration 
and attachment, allows vascular infiltration to bring circulating cells into the scaffold, removes 
waste, and provides nutrients. In the work described in Chapter 5, scaffolds with interconnected 
porosity were fabricated using high enough ratios of porogen volume to scaffolding material 
(ReCaPP cement) volume to ensure porous networks. While these scaffolds can be fabricated with 
a high degree of porosity (~74%), when pore networks are unorganized, resulting scaffolds may 
have regions without pore interconnectivity, and varying, unpredictable mechanical strength [218]. 
Another approach to creating scaffolding with interconnected pores is through the colloidal crystal 
arrangement of porogens. Using monodisperse microspheres arranged into a colloidal crystal 
formation as a template, scaffolding material can be infiltrated through the crystal and hardened. 
Subsequently, by dissolving away the organized microsphere template, the resulting scaffold bears 
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the structure of an inverted colloidal crystal (ICC). This highly organized ICC structure has several 
benefits over scaffolding with random porous networks, such as a high degree of organization, 
uniform pore size, and predictable mechanical strength [218, 219]. Additionally, scaffolding with 
an ordered porous network allows for microarchitecture reproducibility with reliably 
interconnected pores [218, 220-222]. 
In this work, we used microsphere self-assembly techniques to explore the creation of an 
ICC scaffold for bone tissue engineering using ReCaPP cement.  Further, we fabricated 
monodisperse PLGA microspheres loaded with PDGF for the potential future use a growth factor 
eluting porogen in ICC scaffolding.  
As a proof of concept model to refine our fabrication techniques, we first fabricated PLA 
and PLGA ICCs, as several groups have done [219, 223]. In contrast to other porous CaP scaffolds 
with ordered pore structures or those that incorporate the controlled release of biological factors, 
we have incorporated controlled drug release within an ordered ICC composite scaffold to 
biomimetically promote ordered tissue regeneration [110, 220, 224]. By designing a bioactive 
scaffold with an ordered macroporous network, we aim to homogeneously release growth factors 
from localized pockets within the scaffold to recruit cell that will infiltrate the scaffold and create 
new tissue throughout. 
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6.2 MATERIALS AND METHODS 
Monodisperse soda lime and polystyrene microspheres were used to fabricate non-Brownian 
colloidal crystals templates. These templates were then fused and combined with PLGA and 
ReCaPP to produce three-dimensional inverted colloidal crystal scaffolds. Subsequently, we 
investigated the production of monodisperse PLGA microspheres as a growth factor delivery 
component of colloidal crystal scaffolding for potential applications in bone repair.  
6.2.1 Soda Lime Particle Crystalline Templates 
Glass vials (1 mL capacity) containing 150 μg SL particles and 200μL DIW were suspended in the 
sonication bath for 90 minutes. Following sonication, the fluid was allowed to fully evaporate. The 
soda lime crystals were then fused together via calcination for 3 hrs at 680 °C with a ramping rate 
of 15 °C/min in air. Fusion temperatures and times were varied in method development from 670-
690 °C for 2-5 hrs.  
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6.2.2. Polymer-based Inverted Crystals 
Solutions of PLA and 75:25 PLGA in dichloromethane (DCM) (10 wt%) were respectively added 
to the soda lime particle crystals post-fusion and cooling. The solution was added until the crystal 
was fully submerged (~200 µL). After the DCM fully evaporated, the glass vials were cracked and 
the samples were removed and transferred to a Nalgene container containing a 5% HF solution. 
Samples were rotated end-over-end until complete removal of SL particles was achieved as 
monitored on a stereomicroscope. Washing generally occurred over ~8-10 days with a daily 
exchange of wash fluid and end-over-end mixing. On days 4 and 7, the Nalgene container with 
sample was submerged for 10 s in sonication bath, the wash fluid changed and was then returned 
to mixing. On day 8, the sample was washed 5-10X in deionized water, immersed in deionized 
water for 24 hours of mixing and dried for further use. *Note: PS particle-crystals would not work 
in this combination due to the PS’s solubility in DCM. 
6.2.3 Polystyrene Particle Crystalline Templates 
Polystyrene (PS) microspheres (90 and 200 µm in diameter) were organized by agitating a solution 
of polystyrene microspheres in deionized water via sonication. Briefly, 600 μL of particles in 
solution (10 wt% in diH2O) were deposited and sonicated in stainless steel molds (as pictured in 
Figure 40) for 90 minutes. Samples were then fused at 165 °C for 48 hrs and 220 °C for 8 hrs 
respectively. 
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6.2.4 Cement-based Inverted Crystals 
A cement slurry was added with pressure to infiltrate it throughout the particle bed. The cement 
powder (ReCaPP) was prepared by mixing calcium salts and disodium hydrogen phosphate. 
Alpha-tri-calcium phosphate (α-TCP, pure phase, Sigma-Aldrich, USA), calcium carbonate 
(99+%, Acros Organics, USA), calcium sulfate di-hydrate (99+%, Acros Organics, USA), and 
disodium hydrogen phosphate (≥99%, Sigma-Aldrich, USA) were mixed in an agate mortar-pestle 
for 30 min. *Note: SL particle-crystals would not work in this combination due to the cements 
inability to withstand HF washing. 
6.2.4.1 Preparation of ReCaPP Liquids 
The liquid component of the ReCaPP consisted of a colloidal solution of nano-sized calcium 
phosphate (nano-CaPs) homogeneously dispersed in a buffer solution. Details of the nano-CaPs 
preparation can be in Chapter 5. Briefly, for each milliliter of nano-CaPs solution, 250 µl of 0.75 
M CaCl2 was added drop wise to a 250 µl of phosphate precursor solution, pH 7.5, comprised of 
0.357 M NaCl (>99.5%, Fisher Scientific, USA), 13 mM KCl (>99%, Fisher Scientific, USA), 15 
mM dextrose monohydrate (Fisher Scientific, USA), 64 mM HEPES free acid (99.5%, Sigma-
Aldrich, USA) and 1.91 mM of Na3PO4·12H2O (98+%, Acros Organics, Thermo Fisher Scientific, 
USA).  
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6.2.4.2 Cement Preparation and Scaffold Fabrication 
Each of the cement samples was prepared by mixing 250 mg of the cement powder with 150 µl of 
the nano-CaPs solution in a polystyrene pour boat. Once mixed, the cement slurry was loaded into 
a 1.0 mL syringe and deposited on top of cooled PS crystals. A tamping device was then used to 
compress the cement encouraging infiltration through the crystal, filling its voids. Samples of 
cement and PS crystals were then placed in an incubator and allowed to harden for a minimum of 
24 hours while incubated at 37 °C. PS particles were removed via calcination in air at 500 °C for 
3 hrs with a ramping speed of 2.77 °C/min. 
6.2.5 Scaffold Imaging 
Samples were cut using a razor blade for imaging cross-sections. An Olympus ZS100 microscope 
was used to visualize the pore structure of the sample and to watch the cement infiltration prior to 
drying. SEM was also used to image the scaffolds and a sputtercoat thickness ~5 nm was applied 
for imaging. 
6.2.6 PLGA Particle Fabrication for Growth Factor Eluting Colloidal Crystal Construct 
 Double emulsion PLGA microspheres were fabricated by dissolving 200 mg of 50:50 PLGA in 4 
mL of dichloromethane. A 100 μL aliquot of 200 μg/mL soluble PDGF-BB (R&D Systems) was 
mixed with a 100 μL aliquot of NaCl in deionized water to make aqueous solutions with salt 
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concentration ranging from 5 mM to 50 mM. This 200 μL aqueous aliquot, containing both salt 
and PDGF, was sonicated with the dissolved PLGA for 30 seconds at 25% to create a water-in-oil 
emulsion. The resulting solution was then pipetted dropwise through a 250 μm sieve into a 
spinning solution of 1% PVA in deionized water to create water-in oil-in water microspheres of 
approximately 100 μm in diameter.  Following fabrication, the particles were collected via 
centrifugation, washed five times with deionized water. Collected particles were then frozen and 
lyophilized.  
6.2.7 Growth Factor Release from PLGA Particles 
To determine the release rate of PDGF from PLGA microspheres, 10 mg of PLGA microspheres 
were suspended in 1 mL of PBS release solution in a lo-bind Eppendorf tube and subject to end-
over-end rotation at 37ᴼC. PBS release solution consisted of PBS supplemented with SDS (50mM) 
and 0.1% BSA to further prevent released PDGF-BB from sticking to the Eppendorf tube. At 
experimental timepoints, particle suspensions were centrifuged at 1000 RPM and supernatant was 
collected and frozen at -20ᴼC. Fresh PBS was added, particles were re-suspended, and again end-
over-end rotated at 37ᴼC. At the conclusion of the study, all frozen supernatant samples were 
thawed and assayed for PDGF concentration using a human PDGF-BB ELISA assay (R&D 
Systems).  
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6.2.8 Arrangement and Fusion of PLGA Particles 
Poly-lactic-co-glycolic (PLGA) microspheres (with 25 mM and 50 mM NaCl aqueous phases) 
were organized by agitating a solution of PLGA microspheres in deionized water via sonication. 
Briefly, 600 μL of particles in solution (10 wt% in diH2O) were deposited and sonicated in 
stainless steel molds (as pictured in Figure 40) for 90 minutes. Excess water was allowed to 
evaporate overnight. Samples were then fused at 40°C for 10 hrs and for 8 hrs, respectively. 
6.2.9 Monodisperse PLGA Microsphere Fabrication 
Monodisperse microparticles were fabricated using a microfluidics system (Micronit Fluidics) in 
combination with two syringe pumps (New Era Syringe Pumps, Inc.) The first syringe pump was 
loaded with a 50 mL syringe (Norm-Ject) containing a solution of 1% PVA in deionized water. 
The second syringe pump was outfitted with a solution of 800 mg of 50:50 PLGA dissolved in 16 
mL of dichloromethane. The PLGA/dichloromethane solution was sonicated with 800 μL of 25 
mM and 50 mM sodium chloride in deionized water for 60s at 25% power prior to syringe loaded 
to create the first water-in-oil emulsion. The syringe pumps were then connected to the 
microfluidics system, which housed a focussed flow microfluidics chip. With the appropriate 
connections, the PLGA emulsion phase passed through two converging channels of 1% PVA 
solution, creating double emulsion microspheres, which were collected in a 200 mL beaker of 
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static 1% PVA. Several pumping speeds for each phase were evaluated, ultimately, the 1% PVA 
in deionized water was pumped at a rate of 4 mL/hr, while the PLGA emulsion was pumped at 1 
mL/hr. Following collection, resulting microspheres were imaged using a Nikon inverted light 
microscope, then frozen in liquid nitrogen and lyophilized for further use and analysis. 
6.3 RESULTS 
To generate proof-of-concept ICC scaffolding for bone repair, sonication was used to organize 
monodisperse microspheres in the micron size range (diameters of approximately 100 μm) for the 
fabrication of three-dimensional colloidal crystal templates. After optimizing fusion methods, 
these colloidal crystals were infiltrated with PLGA and ReCaPP. Crystal templates were then 
dissolved away, leaving behind highly porous, inverted colloidal crystal scaffolds. Additionally, 
the production and characterization of monodispersed PLGA microspheres was investigated for 
the potential release of growth factors from colloidal crystal scaffolding.  
6.3.1 Inverted Colloidal Crystal Calcium Phosphate Scaffold 
Prior to using calcium phosphate to create inverted colloidal crystals, PLA and PLGA were 
used as infiltration media to create ICCs (Figure 39). Fabrication of ICCS formed using these 
(ond other) polymers is described in detail in the literature, and allowed us to refine our methods 
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before exploring the creation of ICCs using calcium phosphate. SEM imaging of ICCS 
created with PLA and PLGA show a uniform structure and interconnected porous 
network (Figure 39). 
Figure 39. PLA ICC scaffolding, showing a uniform interconnected porous network. Scale bars = 
100 μm. 
Calcium phosphate inverted colloidal crystals (CP ICCs) were produced by first arranging 
monodisperse polystyrene microspheres within a stainless steel mold (Figure 40, A) and fusing the 
resulting hexagonally-packed crystal (Figure 40, B). Once the crystal cooled, calcium phosphate 
was added to the mold and allowed to set (Figure 40, C.) Following CaP setting, infiltrated crystals 
were calcinated for 3 hours at 500ᴼC for 3 hours, leaving behind an the calcium phosphate inverted 
colloidal crystal (Figure 41). Interestingly, differing microstructures were observed in the same 
CP ICC (Figure 42). 
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Figure 40. A) Depiction of steel mold used to fabricate polystyrene particle colloidal crystals, B) 
Resulting colloidal crystal removed from mold following fusion, and C) PS colloidal crystal 
following infiltration with ReCaPP cement. 
A.
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Figure 41. SEM of ReCaPP inverse colloidal crystal following calcination of polystyrene 
particles.  
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Figure 42. SEMs showing regions of the CP ICC in Figure 33, revealing regions of differing 
microstructures 
6.3.2 PLGA Microspheres for Growth Factor Release 
PLGA microspheres were fabricated with a range of NaCl concentrations in the inner aqueous 
phase to create porous microspheres for the facilitation of PDGF release. Examples of the creation 
of porous microspheres via salt concentrations ranging from 5 mM NaCl to 50 mM NaCl (Figure 
43) show that microspheres are increasingly porous with increasing salt concentrations. In Figure
44, an SEM of a microsphere fabricated with a 50 mM inner aqueous salt concentration shows 
resulting porosity across the surface of the microsphere. 
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Figure 43. SEMs of PLGA particles fabricated using different concentrations of salt in the water 
phase, resulting in increasing porosities with increasing salt concentrations 
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Figure 44. SEM of surface architecture porosities of PLGA microsphere produced using a 50 mM 
NaCl concentration in the inner aqueous phase. 
6.3.3 PDGF Release from PLGA Microspheres 
PDGF release was assayed from microspheres fabricated with inner aqueous phases of varying salt 
concentrations (0 mM – 50 mM) PDGF release from microspheres was assayed over the course of 
10 days. As shown in Figure 45, all microsphere formulations had a burst release over the first 2-
3 days of the assay, after which no further release was detected. Additionally, the magnitude of 
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the burst observed increased with increasing inner acqueous salt concentration/microsphere 
porosity. 
Figure 45. PDGF release profiles of PDGF particles with varying salt concentrations in the water 
phase, showing that increasing salt concentration increase the burst release of PDGF. 
6.3.4 Arrangement and Fusion of PLGA Microspheres 
Microspheres with 25 mM and 50 mM inner aqueous NaCL concentration were used in fusion 
experiments. Less porous microspheres (with 25 mM NaCl inner aqueous concentration) were 
fused at 40ᴼC for 10 hours, while microspheres with greater porosity (50 mM NaCl inner aqueous 
concentration) were fused at 40ᴼC for 8 hours. Resulting crystals were imaged (Figure 46), 
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showing that microspheres lost their shape and structure when fused for 10 hours, and at 8 hours 
were no longer spherical, but maintained their surface architecture and porosity. 
Figure 46. SEM micrographs of PLGA microsphere fusion attempts at 40ᴼC for 10 hours and 8 
hours, showing that microspheres begin to melt at 10 hours, and begin to deform at 8 hours, 
suggesting a midpoint in this time range may be more ideal for fusion.  
6.3.5 Monodisperse PLGA Microsphere Fabrication 
Monodisperse PLGA microspheres were fabricated using a focussed flow microfluidics chip 
(Micronit Fluidics) in combination with two syringe pumps – one to pump the water-in-oil growth 
factor/PLGA emulsion, and one to pump a 1% PVA phase. Resulting microspheres of 
approximately 175 μm (when wet) were produced as shown in Figure 47.  
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Figure 47. A microscopic image of monodisperse PLGA microspheres immediately following 
fabrication showing consistently sized microspheres approximately 175 μm in diameter prior to 
freeze-drying. 
6.4 DISCUSSION 
To create a CP ICC, various methods of dissolving microspheres (polystyrene, PLGA) away from 
the scaffold were investigated, including dichloromethane, hydrofluoric acid, dimethyl sulfoxide, 
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and tetrahydrohydrofuran. However, these methods resulted in uneven dissolution of the 
microspheres, and unpredictable swelling of the microspheres during dissolution, which at times, 
compromised the structural integrity of the scaffolding. As an alternative method of microsphere 
removal, scaffolds were heated to temperatures of 500-700ᴼC over time periods ranging from 30 
minutes to 3 hours. Ultimately, it was found that heating the scaffolds at lower temperatures for 
longer time-frames resulted in more complete microsphere removal, and therefore, a more porous, 
organized three-dimensional structure. Interestingly, when the resulting CP ICC was imaged with 
a scanning electron microscope, it was found to have distinct regions of differing microstructures 
(Figure 42). In regions where microsphere imprints are observed, this is likely a result of 
incomplete microsphere fusion, which allowed CaP infiltration fully around the surface of the 
microsphere. Where “bridges” of CaP scaffolding are observed, microspheres had likely fused to 
a greater degree, leaving behind little room for CaP to infiltrate, and resulting in large pore 
“windows.” Ideally, a more consistent microsphere fusion would result in more standard CaP 
infiltration, creating an organized, predictable pore structure throughout the scaffold. 
To incorporate growth factor release into the colloidal crystal template, double emulsion 
PLGA microspheres were fabricated with salt (NaCl) in the inner aqueous phase to create porous 
particles that facilitate PDGF release. Microspheres with inner aqueous salt concentrations of 25 
mM and 50 mM were ultimately chosen for incorporation in ICC scaffolding, as they had the 
greatest porosity of microspheres generated (Figure 44). With increasing microsphere porosity, we 
expected greater growth factor release, which was indeed observed in the magnitude of burst 
release of PDGF (Figure 45). Interestingly, no PDGF release was observed in porous microspheres 
following burst release, indicating that positively-charged PDGF may have bound to the 
negatively-chardged degrading PLGA [208]. Another explanation for this behavior may be that 
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the swelling of inner pockets of the microspheres containing PDGF caused rupture of the 
microsphere, resulting in immediate burst release of its contents [225, 226]. 
To fuse PLGA microspheres and create the template for the colloidal crystal scaffolding, a 
low temperature (40ᴼC) was chosen for several reasons: 1) the known melting point of PLGA 
ranges from 60ᴼC to over 200ᴼC, (depending on molecular weight and polymer ratio)[227, 228] 
2) growth factors such as PDGF become inactivated at higher temperatures (in excess of 100ᴼC
[229]), and 3) as found in our previous experiments, both the fusion and calcination of 
microspheres occurs more uniformly at lower temperatures over longer time periods. In addition 
to choosing to fuse microspheres at 40ᴼC, two time periods were explored for fusing PLGA 
microspheres: 8 hours and 10 hours. Microspheres with high porosity (50 mM inner aquous salt 
concentration) were fused for less time (8 hours) in anticipation of their high porosity speeding 
fusion. It was found that while microspheres began to deform after 8 hours, they did not fuse to 
one another, indicating a longer fusion period may be necessary (Figure 46). However, when 
microspheres were fused for 10 hours, they deformed greatly, melting to the point of losing their 
spherical structure (Figure 46). Together, these results indicate that a midpoint between 8 and 10 
hours of fusion at 40ᴼC may be more appropriate for fusing PLGA microspheres in this application. 
As shown in Figure 47, when generating monodisperse PLGA microspheres, pumping 
speeds of 4 mL/hr for the 1% PVA phase and 1 mL/hour for the PLGA single emulsion phase were 
found to generate microspheres of approximately 175 μm in diameter immediately following 
fabrication (before dehydration and freezing.) Microspheres of this size are acceptable for use in 
the fabrication of an ICC scaffold, as microspheres ranging from 100-200 μm are recognized to 
generate pores of a size that will allow angiogenesis formation and diffusion throughout the 
scaffold [230-232].  
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6.5 CONCLUSIONS 
In these experiments, we have shown the possibility of creating an inverted colloidal crystal 
scaffold with calcium phosphate cement. Additionally, we have fabricated our own monodisperse 
PLGA microspheres capable of releasing PDGF in a predictable manner and explored the fusion 
of these microspheres into a colloidal crystal template. Together, these results can be further 
optimized and combined to create a CP ICC capable of controllable releasing growth factors. The 
work performed in this chapter demonstrates the potential for the fabrication of a calcium 
phosphate-based inverted colloidal crystal scaffold capable of releasing growth factors to promote 
cell infiltration, and ultimately, the regeneration of new tissue. Through continued collaboration, 
fabrication techniques may be refined to create a more consistent porous network and to explore 
cellular responses to growth factor release from this hierarchically organized structure. 
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7.0 CONCLUSIONS AND FUTURE OUTLOOK 
We have utilized a three dimensional, in vitro model that permits the exploration of the effects of 
growth factor timing on vascularization in the context of bone repair with a large degree of 
variables. Specifically, we were able to evaluate resulting tubule formation from variations in 
sequence, length, and degree of overlap in growth factor delivery. We observed that the sequence 
of angiogenic (PDGF) to osteogenic (BMP-2) presentation resulted in greater tubule formation 
than the reverse presentation or co-delivery of these growth factors. Additionally, moderate 
overlap (2-4 days) in the sequence of PDGF to BMP-2 delivery resulted in greater tubule formation 
in comparison to the absence of overlap as well as prolonged overlap. Using PLGA microspheres, 
alginate hydrogels, alginate microspheres, and ReCaPP cement, we fabricated an osteoconductive, 
three-dimensional, porous scaffold capable of controllably releasing a programmed schedule of 
PDGF and BMP-2 delivery. With this combination of materials, we stimulated the infiltration of 
ReCaPP scaffolding by hMSC and HUVEC co-cultures in response to a PDGF gradient. 
Additionally BMP-2 that was controllably released from alginate microspheres in the ReCaPP 
scaffold promoted ALP expression in hMSCs cultures on both day 7 and day 14 time-points. Using 
alginate microspheres, ReCaPP cement, polystyrene microspheres, and PLGA microspheres, we 
have begun to explore additional scaffolding and assaying techniques that may lead to greater 
advances in the efficacy of these controlled release systems. These approaches may be further 
applied to investigate the effects of growth factor timing, overlap, and sequence on additional cell 
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types, later time points to gather information that may lead to improved in vivo outcomes. The 
resulting information could serve as a valuable contribution to our understanding of the effects of 
growth factor timing and sequence in the bone regeneration niche, and ideally, advance the 
development of growth factor therapies for fracture repair. 
Traditional methods used clinically for fracture repair, on a daily basis, are something you 
may expect of more primitive times; hammers, chisels, and saws are used to cut bone from one 
location in the living human body, that is then nailed into the site of fracture to promote healing. 
Even recent technologies, like the incorporation of BMP-2 into synthetic scaffolding still has many 
limitations; it is currently broadly delivered in large quantities, and while sometimes effective, has 
also led to complications such as ectopic bone formation and fused spinal vertebrae. At this 
moment, we are at the beginning of understanding the complex in vivo healing processes, that is, 
how cells and growth factors communicate with each other over space and time to orchestrate a 
multi-stage cascade of cellular event. This body of work serves to bring the field a step closer in 
understanding these complex behaviors, and in response, creating new biomaterials that begin to 
take these complexities into account when designing a new generation of growth factor delivery 
scaffolding for bone repair. 
The future testing and development of these growth factor technologies for regeneration 
intersects with a fascinating moment in the US government’s classification and regulation of 
biologically active medical devices. While both BMP-2 and PDGF-BB have been approved for 
different applications in clinical use, there remain serious side effects and complications associated 
with growth factor delivery for regeneration. Particularly in the case of BMP-2 delivery, 
overproduction of bone growth (and in some cases, undesired bone fusion) has soured the 
enthusiasm once held for these therapies. Additionally, there has yet to be a product approved for 
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clinical use that elutes multiple recombinant growth factors. Although products such as platelet–
rich plasma, which contain a variety of growth factors are approved for some clinical applications, 
they fall under the “biologics” classification of the FDA, and are regulated by the Center for 
Biologics Evaluation and Research. When combining multiple biologically active agents 
(particularly recombinant proteins) with scaffolding material engineered to provide controlled 
release, we reach an undefined, grey area between “medical device” and “biologic” FDA 
classification. While controlled release technologies may assuage some of the drawbacks of 
multiple growth factor release in clinical applications (such as mitigating ectopic bone formation 
and cutting costs by delivering lower growth factor concentrations) there still remain unanswered 
questions in the approval and implementation processes of such products. 
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APPENDIX 
CONFIRMING CELLULAR STRUCTURES WITH SCANNING ELECTRON 
MICROSCOPY 
While cells are sometimes difficult to identify within scaffolds using scanning electron 
microscopy, several studies have validated the use of SEM to analyze cells specifically within 
calcium phosphate scaffolds [233-236]. For the purposes of identifying cell infiltration in these 
studies, calcium phosphate scaffolds were imaged from the top (where cells were seeded), from 
the bottom (opposite side from where cells were seeded), and along a top-to-bottom vertical cross-
section at approximately the diameter of the cylindrical scaffold. Cells were identified to be 
spindle-like structures within the pores of the scaffolds that are visually similar to the appearance 
of cells identified via SEM in calcium phosphate scaffolds of comparable studies [233, 234]. 
Spindle-like cell structures observed in the cross-sections of scaffolds can be more clearly seen in 
Figure 48, which depicts the top of a scaffold in the PDGF + BMP treatment group. These 
structures were absent from the bottom images of all scaffolds, an example of which can be seen 
in Figure 49. Other methods of microscopically identifying cells within the scaffold are limited 
because calcium phosphate is opaque, and therefore, cannot be penetrated by a light source that is 
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required by most microscopy methods. As a potential alternative to SEM, a top-lit confocal 
microscope, however, this resource is not currently available for use at our imaging facilities. 
Figure 48. The top surface of a scaffold at experimental day 10, where a co-culture of HUVECs 
and hMSCs were seeded on day zero, showing spindle-like cellular structures within the surface 
pores of the scaffold. 
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Figure 49. The bottom surface of a scaffold on experimental day 10, opposite the site of cell 
seeding, showing an absence of spindle-like cellular structures from the surface or pores of the 
scaffold. 
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